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Aims oft he study  
1 Aims of the study  
In our experiments, SKBR3 and T47D, two human breast cancer cells proved to 
be sensitive and resistant against a particular epidermal growth factor receptor 
(EGFR)/ErbB-2 receptor tyrosine kinase inhibitor pelitinib (EKB-569), 
respectively. The aim of the project is to delineate the major signaling pathways 
downstream of the ErbB family of receptor tyrosine kinases (RTKs) in these two 
human breast cancer cell lines. We examined the effects of pelitinib on the 
phosphatidylinositol-3 kinase (PI3K) pathway and on the mitogen-activated 
protein kinase (MAPK) downstream signaling cascade. Proliferation data of 
these cells exposed to different concentrations of pelitinib, rendered SKBR3 
sensitive and T47D resistant. Interestingly, differences in AKT phosphorylation 
levels were observed. To establish a solid basis for further statements of 
inhibitor sensitivity/resistance in these human cancer cell lines AKT activation 
and its ability to render cells resistant was examined by transfection procedures 
of sensible SKBR3 with constitutive active myr-AKT1 plasmids.      
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2 Introduction  
2.1 Breast cancer 
2.1.1 The geographical distribution and mortality incidence of breast 
cancer  
In industrialized countries breast cancer is one of the most common cancers of 
women and more than 1 million cases are diagnosed with a mortality incidence 
of 500 000 death per year in the whole world (Benson et al., 2009). In earlier 
times breast cancer was not theme in not-industrialized countries but nowadays 
the disease rate increases. Peggy Porter (2008) reported the `Westernization` 
as a higher risk to increase breast cancer rates in Japan, Korea, Singapore, 
China, India and Africa.                  
Fig.1: Incidence rates (top panel) and mortality rates (bottom panel) of breast 
cancer (Peggy Porter, 2008). Data are from GLOBOCAN 2002, International Agency 
for Reasearch on Cancer. 
  
- 12 -  
Introduction  
Anyway, East Asian woman represent lower incidence rates of breast cancer, 
about 21 per 100,000 compared to the United States, Europe and Australia with 
101 per 100.000 the highest incidence rate, respectively. Moreover, Western 
Europe represents an incidence rate of breast cancer about 85 per 100,000 
(Fig.1). Interestingly, while African women still have lower incidence rates, 23 
per 100,000, when compared to other countries except East Asia, local 
registries report in Africa two-fold higher incidence rates compared to the past 
40 years. Nevertheless, the incidence rates of breast cancer increases 
worldwide, thus the mortality incidence continue to rise, with about 29,6 to 20 
per 100,000 in the United States, Europe, Western Europe and Australia 
(Fig.1). Although the mortality rates have increased the past years in Africa and 
Asia the mortality rates tend to be much lower, under 20 per 100,000, when 
compared to the rest of the world.  
2.1.2 Breast cancer-risks and the modulating factors  
Previous studies reported different risk factors which are associated with breast 
cancer development, such as genetic predispositions, hormones and 
reproductive patterns (Benson et al., 2009 and Hankinson et al., 2004). Risk 
factors such as decreasing age at menarche, late age at menopause, nullparity 
and reduced breast feeding have been known for many years. Moreover, 
different diet strategies and obesity in Western countries are associated with 
breast cancer development. Often genetic predispositions play crucial roles in 
human cancer development. Years ago, tumor suppressor genes have been 
identified, including BRAC1, BRAC2, and PTEN, to be associated with breast 
cancer-risks. It was reported that 5-10% of all breast cancer are hereditary and 
due to mutations within these two genes BRAC1 and BRAC2 (Robson et al., 
2007).  
As early as in the 1800s, it was recognized that estrogen plays an important 
role in the development and progression of human breast cancer. Many years 
later the estrogen receptor (ER) was identified and nowadays is used as an  
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important breast cancer phenotypic and prognostic parameter. Breast cancer 
risks due to hormone dependency, includes estrogen-receptor-positive tumors 
which are stimulated by estrogens and estrogen-receptor-negative tumors, 
which emanates from the former by possible lesions. Furthermore, hormone-
replacement therapies (HRT) are methods for treatment of menopausal woman 
with diminished circulating estrogens and progesterone. Holmberg et al., (2008) 
reported HRTs as reasons which double the risks of recurrence in patients who 
have survived breast cancer. 
Interestingly, alcohol consumption also correlates with breast cancer-risk in 
women through its effects on estrogens (Zhang et al., 2007). Moreover this 
paper has investigated the relation of alcohol intake and ER+PR+ tumors, 
whereas ER-PR- and ER+PR- tumors are not associated with alcohol 
consumption, like the Swedish Mammography Cohort study has revealed but in 
contrast to the Women`s Health study. These data suggest high association 
between alcohol consumption and breast cancer-risk mediated by the estrogen 
pathway.  
2.1.3 Diagnosis of breast cancer  
In patients with breast cancer, complete clinical evaluations of different factors 
have to be revealed, and for best therapeutic measures a rough estimate on 
local disease extent is made. Mammographic screening leads to the detection 
of malignancy and even reduces breast cancer-mortality in postmenopausal 
women. Furthermore, complementary to mammography (MMG), whole-breast 
ultrasonography (US) provides measurement of tumor size and increases 
diagnostic estimates of malignant foci. These both imaging technologies enable 
enhanced prevention of breast cancer development and further implicate exact 
coordination of patient treatment (Benson et al., 2009). For exact tissue 
diagnosis for benign or malignant diseases fine-needle aspiration cytology or 
core biopsy are used, whereas core biopsy enables higher specificity and 
sensitivity as compared to the former (Britton et al., 1999). To detect the extent  
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of a lesion of breast cancer in its accuracy, magnet resonance imaging (MRI) 
remains to be a diagnostic imaging method reported by Mameri et al., (2008).   
2.1.4 Primary systemic and adjuvant-systemic therapies in breast cancer  
Breast cancer is known to be a complex and heterogeneous disease and its 
biology is poorly understood. Primary treatment of breast cancer includes 
lumpectomy, radiotherapy and radical mastectomy, whereas adjuvant therapy is 
additional to provide long-term survival and avoid recurrence of the tumor. 
Ravdin et al., (2001) reported improvements of a computer program Adjuvant 
to decide about right adjuvant therapies, such as chemotherapy, hormone 
therapy or chemoendocrine therapy, dependent on tumor staging and 
characteristics. Therefore, systemic investigations characterize the existence of 
multiple subtypes of breast cancer, such as basal-like, ErbB-2 overexpressing, 
normal breast-like, luminal subtypes A,B,C using gene expression pattern 
profiles (Sorlie et al., 2001). The first target-based endocrine therapy was the 
treatment of luminal subtypes of estrogen receptor positive (ER+) breast cancer 
cells, with the selective estrogen receptor modulator (SERM) tamoxifen, the 
most effective systemic treatment since 100 years, responsible for reduction in 
mortality and local recurrence. Aromatase inhibitors and fulvestrant represent 
new developed drugs in treatment of post-menopausal breast cancer after 
disease progression following anti-estrogen therapies. Nevetheless, patients 
can respond poorly to endocrine therapies, irrespective of used endocrine 
agents, which can be associated with activated AKT a downstream mediator of 
ErbB-2 overexpressed in many ER+ breast carcinomas (Tokunaga et al., 2006).    
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2.2 ErbB tyrosine kinase receptors  
2.2.1 ErbB tyrosine kinase receptors  
The ErbB receptor network comprises a signaling transduction system which is 
involved in the process of malignant transformation during cancer development 
(Yarden et al.,2006). Darcy et al., (2000) reported involvement of all ErbB 
members in mammary gland development and expression of various cell-type 
specific patterns during growth, differentiation and apoptosis. This family 
consists of four homologous members: ErbB-1/HER-1/EGFR, ErbB-2/HER-
2/Neu, ErbB-3/HER-3 and ErbB-4/HER-4. All family members have an 
extracellular ligand-binding domain, a short hydrophobic transmembrane 
domain and a cytoplasmic tyrosine kinase domain that plays a significant role in 
regulating cellular processes in cancer.   
2.2.2 ErbB-specific ligands and ErbB-receptor heterodimerisation  
ErbB receptors are activated by four categories of ErbB-specific ligands such as 
EGF-related peptide growth factors (Fig.2). For epidermal growth factor-
receptor (EGFR) the following ligands are known: amphiregulin (AR), 
betacellulin (BTC), epidermal growth factor (EGF), epiregulin (EPR), heparin-
binding EGF-like ligand (HB-EGF), and transforming growth factor  (TGF ). 
EGFR binds EGF, AR and TGF- , whereas BTC, HB-EGF and EPR can bind 
either to EGFR or to ErbB-4.  The neuregulins (NRGs) or heregulins (HRGs) 
represent a large number of differently spliced proteins that bind to ErbB-3 and 
4. NRG1 and NRG2 bind both ErbB-3 and ErbB-4 receptor, but NRG3 and 
NRG4 only bind to the ErbB-4 receptor.    
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Fig.2: ErbB-specific ligands (Olayioye et al., 2000). EGFR bind the following 
ligands, which are EGF, transforming growth factor (TGF ) and amphiregulin (AR). 
Betacellulin (BTR), epiregulin (EPR) and heparin-binding EGF-like ligand (HB-EGF) 
bind both EGFR and ErbB-4. The neuregulins (NRGs) represent NRG1 and NRG2 that 
bind to ErbB-3 and 4, whereas NRG3 and NRG3 only bind ErbB-4.  
The receptors are phosphorylated upon ligand binding and form homo- or 
heterodimers. The nature of the ligand determines the ErbB dimers which are 
formed. However, it has to be mentioned that ErbB-2 does not have a cognate 
ligand implicating that it does not represent a true receptor. It rather acts as a 
dimer partner and co-receptor for the other ErbB receptors. ErbB-2 is the most 
preferred dimerisation partner for EGFR, ErbB-3 and ErbB-4 receptor (Fig.3). 
Fig.3: ErbB-receptor homo- heterodimerisation (Olayioye et al., 2000). Formation 
of homo- and heterodimers, whereas ErbB-2 is the most preffered heterdimerisation 
partner for EGFR, ErbB-3 and ErbB-4. ErbB-3 exhibits a degenerated tyrosine kinase 
domain and cannot signal on its own. 
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On the other hand, the tyrosine kinase domain of ErbB-3 is degenerated and 
thus functionally invalid. Consequently, ErbB-2 and ErbB-3 cannot signal on 
their own, but rather need a dimerisation partner for signaling. ErbB-2 is 
strongly activated after heterodimerisation with ligand-activated EGFR, ErbB-3 
or ErbB-4, whereas ErbB-2 and ErbB-3 heterodimers tend to be the most 
favored ErbB constellation under the ErbB heterodimers. Anyway, EGFR and 
ErbB-2 are frequently overexpressed in cancer and correlate with a more 
aggressive clinical behavior and poor prognosis (Olayiode et al., 2008).   
2.2.3 ErbB-specific downstream signaling and cross talk with other 
regulatory systems  
After receptor dimerisation mediated by specific ligand binding, the cytoplasmic 
kinase domain of the receptor is activated and triggers autophosphorylation of 
the C-terminal tyrosine residues. These tyrosine residues provide docking sites 
for molecules with a src homology 2 (SH2) and a phosphotyrosine binding 
(PTB) domain, such as adapter proteins and different kinases. The most 
important signaling pathways are the phosphatidylinositol-3 kinase (PI3K)/AKT 
pathway, the mitogen-activated protein kinase (MAPK) signaling pathway as 
well as the signal transducer and activator of transcription (STAT), the phospho 
lipase C (PLC) and pospholipase D pathways (Marmor et al., 2004). The best 
characterized signaling cascades, which signal via the ErbBs are the PI3K/AKT 
and the MAPK pathways. Apart from these classical downstream pathways, 
ErbB receptors have increasingly be recognized as a family of receptors that 
cross talks with nuclear receptors such as the clinical important and relevant 
estrogen receptor (Grunt et al., 1995; Tang et al., 1996 and Saceda et al., 1996) 
and retinoid receptors (Flicker et al., 1997; Grunt et al., 1998; Offterdinger et al., 
1998, 1999; Schneider et al.,1999; Grunt, 2003 and Grunt et al., 2005)    
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2.2.4 The phospatidylinositol-3 kinase (PI3K)/AKT signaling pathway  
After ligand-induced activation of the ErbB receptor family, the PI3K-PDK1 
(Vanhaesebroeck et al., 2000) signaling pathway activates protein kinase 
B/AKT and promotes proliferation survival, growth, glycogen synthesis, survival 
and nitric oxide (NO) synthesis (Fig.4), and is associated with tumorigenesis 
(Testa et al., 2001 and Nicholson et al., 2002). First, the p85 regulatory subunit 
of the PI3K docks on the phosphorylated tyrosine residues and recruits the 
second catalytic subunit p110 of the PI3K. After the activation of PI3K, it 
transforms phosphatidylinositol 4,5 phosphate (PIP2) into phosphatidylinositol 
3,4,5 phosphate (PIP3). After PIP2 is converted to PIP3 the phosphoinositol-
dependent kinase-1 (PDK1) is recruited to the membrane via its pleckstrin 
homology (PH) domain. Furthermore PDK1 phosphorylates AKT at residues 
threonine 308 and serine 473, which is also recruited to the plasma membrane 
because of its PH domain. 
Fig.4: The phospatidylinositol-3 kinase (PI3K)/AKT signaling pathway (Cell 
Signaling Technology, http://www.cellsignal.com, slightly modified). The 
mechanisms of AKT activation is mediated by phosphorylation of the PI3K through the 
ErbBs.  
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In addition, the PI3K/AKT-pathway has major importance in normal cellular 
homeostasis and cancer growth due to its central role as a cross-over point 
between growth, differentiation and apoptotic pathways and major metabolic 
systems such as tumorgenic lipogenesis (Grunt et al., 2009).  
2.2.5 The mitogen-activated protein kinase (MAPK) signaling pathway  
The ErbB family members signal via the adaptor proteins Grb2 or Shc and 
activate the MAPK signaling pathway (Olayioye et al., 2000). Ras a small GTP- 
binding protein recruits after conformational change Raf-1 (c-Raf) to the 
membrane, where it is phosphorylated on serine/threonine and tyrosine 
residues. Raf1 activates the MEK-ERK signaling pathway and phoshorylates 
Myc and Elk two transcription factors, which control various biologic processes 
by modulating gene expression (Fig.5). The RAF/MEK/ERK pathway therefore 
plays a crucial role in tumorgenesis and by regulating gene expression and 
preventing apoptosis (McCubrey et al., 2006). 
Fig.5: The mitogen-activated protein kinase (MAPK) signaling pathway (Cell 
Signaling Technology, http://www.cellsignal.com, slightly modified). Gene 
expression triggerd by activation of Ras and Raf, which activate the MEK/ERK 
signaling pathway.  
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2.2.6 Targeting ErbB receptors in cancer development  
Signaling through the ErbB receptor family correlates with human cancer 
development and therefore serves as perfect target for different drugs (Citri et 
al., 2006). Nowadays, ErbB-neutralizing monoclonal antibodies, ErbB-specific 
tyrosine kinase inhibitors (TKIs) and inhibitors of heat-shock protein-90 (HSP90) 
are in clinical development (Fig.6). For treatment of breast cancer the ErbB-2 
antibody trastuzumab (herceptin) is in use and for colorectal cancer the 
monoclonal EGFR antibody cetuximab (erbitux) is clinically relevant, and 
pertuzumab (omnitarg) targets heterodimerisation of ErbB-2 as novel 
therapeutic agent. Monoclonal antibodies inhibit not only ErbB receptor 
signaling, but also recruit cytotoxic T-cells. Further achievements are small 
molecule TKIs, such as gefitinib (iressa) and erlotinib (tarceva), which inhibit the 
kinase domain of the EGFR receptor by blocking the ATP binding pocket. 
Gefitinib and erlotinib are two reversible small molecule TKI`s and are approved 
for non-small-cell lung cancer (NSCLC). More effective are dual-receptor TKIs 
such as lapatinib and pelitinib (EKB-569), a new generation of drugs targeting 
both EGFR and ErbB-2. Important for the stability of the ErbB-2 receptor is the 
HSP90 chaperone, which serves therefore as perfect target for new inhibitors 
such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG).            
  
- 21 -  
Introduction  
Fig.6: Targeting ErbB receptors (Citri et al., 2006). Monoclonal antibodies 
cetuximab, pertuzumab and trastuzumab, as well as tyrosine kinase inhibitors (TKIs) 
gefitinib, erlotinib and lapatinib and heat-shock protein 90 (HSP90) inhibitors such as 
17-AAG are in clinical use or in clinical development.  
2.2.7 EGFR overexpression and resistance mechanisms  
Nicholson et al. (2001) reported EGFR expression to be a strong prognostic 
marker in head, neck, ovarian, cervical, bladder and esophagus cancer, 
whereas in non-small-cell lung cancer, EGFR expression acts as a weak 
prognostic factor. In the situation of breast, esophagus, colorectal, gastric and 
endometrial cancer EGFR is a modest prognostic factor. In breast cancer, 
EGFR expression correlates with decrease in patient survival and also acts as 
early prognostic factor suggesting EGFR triggers in cancer development more 
efficiently cell growth and cell progression. Elevated levels of EGFR in breast 
cancer are associated with poor prognosis and loss of sensitivity against 
endocrine therapies (Nicholson et al., 1994). In preclinical studies, breast 
cancer cells were treated with EGFR TKI gefitinib (iressa) and showed growth 
inhibition of breast cancer cells by dephosphorylation of EGFR, ErbB-2 and  
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ErbB-3 receptor resulting in down-regulation of  AKT activity (Moasser et al., 
2001 and Anido et al., 2003). Anyway, resistance mechanisms against the oral 
TKI gefitinib were shown in breast cancer cells that co-express EGFR, ErbB-2 
and ErbB-3. Sergina, et al. 2007 reported the escape of EGFR-TKIs through 
ErbB-2-dependent activation of the ErbB-3/PI3K/AKT pathway. However, 
Normanno, et al. 2008 demonstrated development of resistance mechanisms to 
the drug in breast cancer cells, because of a persistent EGFR-independent 
activation of MAPK signaling pathway. Another EGFR receptor TKI is erlotinib 
(tarceva), an oral reversible inhibitor, which inactivates EGFR downstream 
signaling as well as the ErbB-2 receptor irrespective of the former (Schaefer et 
al., 2007). Anyway, cetuximab (erbitux), a chimeric human-mouse anti-EGFR 
monoclonal antibody undergoes testing in colorectal cancer, head & neck 
cancer and NSCLC as addition to chemotherapy (Stern et al., 2004).  
2.2.8 ErbB-2 overexpression and resistance mechanisms  
A crucial marker for clinical management of breast cancer is the ErbB-
2/HER2/neu receptor, which belongs to the large family of ErbB receptor 
tyrosine kinases. ErbB-2 is overexpressed in 20-30% of breast tumors and 
serves as a perfect target for therapeutic agents. The first clinically approved 
drug targeting ErbB-2 in ErbB-2 positive cancer was trastuzumab (herceptin) 
(Ginestier et al., 2007 and Pal et al., 2007). Trastuzumab is a humanized 
monoclonal antibody with high specificity and affinity for the ErbB-2 extracellular 
domain. In metastatic breast cancer trastuzumab serves either as single 
therapeutic agent or is combined with chemotherapy (Stern et al., 2005). ErbB-2 
overexpression and hyperactivation stimulate the MAPK and the PI3K/AKT 
pathway, and promote cell cycle progression. ErbB-2 overexpression combined 
with PI3K/AKT activation mediates multidrug resistance in breast cancer cell 
lines (Knuefermann et al., 2003). Most of the patients with metastatic breast 
cancer respond to trastuzumab but disease progression was seen within one 
year. Whilst trastuzumab inhibits ErbB-2 receptor signaling, EGFR forms  
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homodimers or EGFR/ErbB-3 heterdodimers and signals via the PI3K/AKT and 
the MAPK signaling pathway rendering breast cancer cells resistant against 
trastuzumab. Thus, combination therapies, herceptin with TKIs, such as gefitinib 
and pertuzumab a monoclonal antibody, will be new therapeutic strategies. As a 
new therapeutic agent, pertuzumab inhibits ErbB-2/EGFR and ErbB-2/ErbB-3 
heterodimers (Natha et al., 2006). Other EGFR/ErbB2-dual targeting drugs 
tested in breast cancer include the small molecule tyrosine kinase inhibitors 
lapatinib and pelitinib (EKB-569). Nahta et al. (2007) reported induction of 
apoptosis in trastuzumab resistant breast cancer cells after treatment of 
lapatinib, whereas pelitinib a new irreversible inhibitor is referred to be in clinical 
trials in NSCLC and colon cancer (Wissner et al., 2008)  
2.2.9 ErbB-3 overexpression and targeted therapies  
Similar to ErbB-2, ErbB-3 overexpression correlates with aggressive clinical 
behavior of breast cancer (Sithanandam et al., 2008). Although ErbB-3 has a 
deficient kinase domain and ErbB-2 is lacking a specific ligand, the ErbB-
2/ErbB-3 heterodimer yet constitutes the most active signaling complex and 
signifies clinically aggressive tumors. Moreover, resistance mechanisms against 
TKIs are often shown in breast cancer cells that co-express EGFR, ErbB-2 and 
ErbB-3. ErbB-3 upregulation in breast cancer cells is associated with resistance 
against different TKIs. Therefore, ErbB-3 overexpression provides EGFR-TKIs 
escape through the possibility of ErbB-3/PI3K/AKT signal pathway activation 
mediated by ErbB-2-dependent signaling (Sergina et al., 2007). Furthermore, 
downregulation of ErbB-3 by RNA interference abrogates secondary resistance 
to TKIs and induces apoptosis.  
2.2.10  ErbB-4 overexpression   
The fourth member of the ErbB family termed ErbB-4 exhibits different functions 
compared to the other ErbB receptors. ErbB-4 can signal as full lengths  
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membrane protein via the PI3K and MAPK signaling pathway, but can also 
translocate as soluble receptor to the nucleus after its processing. It has to be 
noted that all ErbB receptors have already been reported to be localized not 
only in the cell membranes, but also in the cell nuclei. Interestingly, full length 
EGFR (Lin et al., 2001), ErbB-2 (Dillon et al., 2008) and ErbB-3 (Offterdinger et 
al., 2002) have been found in the cell nuclei, where they can act as regulators of 
gene transcription. The biochemical mechanisms of nuclear entry and 
localization of these membrane proteins is still not fully elucidated.  Not only the 
full-length and cleaved ErbB-4 plays essential roles, even spliced ErbB-4 
isoforms must be considered in breast cancer patients. Therapeutic agents 
have been developed to target EGFR, ErbB-2 but relatively little is known about 
the biological significance of ErbB-4 in breast cancer. Experimental studies of 
ErbB-4 show that it is not overexpressed in breast cancer and when ErbB-2 
overexpressing cells are forced to overexpress ErbB-4, it can be associated 
with a reduction of cell proliferation and increase of apoptosis. Therefore, ErbB4 
expression is considered a marker of survival in breast cancer. Interestingly, it 
was described that ErbB-4 overexpression can also be associated with cell 
growth and cell progression, suggesting differences in breast cancer subtypes, 
according to ER+ and ER- tumors. Breast cancer cells, which overexpress 
ErbB-4 in ER+ tumors, are associated with favorable prognosis. (Sunvall et al., 
2008). 
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3 Material and methods  
3.1 Cell culture and cell lines  
3.1.1 List of used materials  
T25 tissue culture flasks 50ml/25cm2: Falcon, 35/3108 
T75 tissue culture flasks 250ml/75cm2: Falcon, 35/3111 
60x15mm tissue culture dishes (petri dishes): Corning, 8430166 
6-well plates: Corning Incorporated, 3506 
96-well plates flat bottom: TPP 92696 
0,05% Trypsin-EDTA: GIBCO, Cat.No. 25300-054 
MEM alpha w/nucleosides. : GIBCO, Cat.No. 22571-020  
D-MEM high glucose (4500mg/l): GIBCO, Cat.No. 41965-039 
Fetal calf serum (FCS): S-America, GIBCO, Cat.No. 10270-106 
Penicillin/Streptomycin: GIBCO, Cat.No. 15140-148 
L-Glutamin 200mM: GIBCO, Cat.No. 25030-032 
Dulbecco`s sulphate buffered saline (D-PBS): GIBCO, Cat.No. 14190 
Recombinant epidermal growth factor (EGF): Sigma, E9644, 100µg/ml  
Recombinant human heregulin ß1 (HRGß1): Thermo Fisher Scientific, RP-
318-P1A,1nM  
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3.2 Cell lines  
The SKBR3 cell line
The SKBR3 breast adenocarcinoma 
cell line descends from human 
mammary gland. This cell line was 
taken from a 43 years old female. 
SKBR3 is cultivated in D-MEM and 
supplemented with 10% heat 
inactivated fetal calf serum (FCS) 
and 1% 100U/ml penicillin, 
100µg/ml streptomycin and 2mM L-
glutamine (PSG). The cells were 
subcultured once a week at a ratio 
of 1:7. 
Fig.7: Morphology of SKBR3   
The T47D cell line
T47D represents a ductal 
carcinoma and was isolated from 
human mammary gland. This 
breast cancer cell line descends 
from a 54 years old female. T47D 
is maintained in D-MEM 
supplemented with 10% FCS and 
1% PSG. The cells were 
subcultured once a week at a ratio 
of 1:10.  
Fig.8: Morphology of T47D 
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The CaOV3 (HTB-75) cell line
CaOV-3 (HTB-75) cells descend 
from a human ovarian 
adenocarcinoma. This cell line is 
cultivated in D-MEM supplemented 
with 10% FCS and 1% PSG. CaOV-
3 (HTB-75) cells were subcultured 
once a week at a ratio of 1:12.     
Fig.9: Morphology of CAOV-3 (HTB-75)   
The SKOV3 cell line
SKOV3 cells were isolated from 
human ovarian adenocarcimoma. 
This cell line is maintained in -
MEM supplemented with 10% FCS 
and 1% PSG. The cells were 
subcultured once a week at a ratio 
of 1:13.     
Fig.10: Morphology of SKOV3     
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3.3 Cell culture and passaging of cells  
All cell lines (Figs.7-10) were cultured in two T 25 tissue culture flasks in 6 ml 
each of the respective medium containing 10% FCS with 1% PSG. Cells were 
passaged at a confluence of 95-100%. After removal of the culture medium 
cells were washed carefully with Dulbecco's phosphate buffered saline (D-PBS) 
and incubated for 5 min at 37°C, 5 % CO2, 95 % humidity with trypsin 
ethylenediaminetetraacetic acid (EDTA) to detach the cells. These cells were 
resuspended in the respective medium and plated in two new T25 culture flasks 
at a ratio of 1:7 to 1:13. The cells were passaged once a week. In some cases 
cells were exposed to 100ng/ml EGF at various times and 3min to heregulin ß1 
(HRGß1).  
3.4 Used drug  
Pelitinib (EKB-569), an irreversible tyrosine kinase inhibitor (TKI) was 
generously provided from Wyeth (Fig.11). It targets both the epidermal growth 
factor (EGFR) and the human epidermal growth factor receptor-2 
(EGFR2/HER2/ErbB-2) and inhibits the function of the kinase domain.  As 4-
anilino-3-cyano quinoline derivative it forms a covalent link with conserved 
cysteine residues, Cys-773 (or Cys-797) in EGFR and Cys-805 in ErbB-2.  
Fig.11: Structure of pelitinib (EKB-569), (Wissner et al., 2008)  
EKB-569 currantly undergoes clinical trial for non-small cell lung (NSCLC) and 
colon cancer. 
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3.5 Proliferation assay  
1,5x 103 cells per well were seeded in 96-well plates in culture medium 
containing 10% FCS with 1% PSG. These cells had to attach overnight and 
were controlled under the microscope. After 24 hours incubation the inhibitor 
pelitinib (EKB-569) was added at different concentrations in culture medium 
without FCS, to obtain a final concentration of 5% FCS per well. Three wells 
were analyzed per treatment condition. Blank wells were devoid of cells and 
consisted culture medium with 5% FCS.  Controls were treated with the vehicle 
(DMSO) only.  
After 72 hours of pelitinib treatment, a growth assay, called EZ4U (Biomedica, 
BI-5000) was performed. This assay is a non radioactive cell proliferation and 
cytotoxicity test. After adding the reagent to the 96-well plates the color of the 
medium changes because living cells with active mitochondria reduce a yellow 
colored tetrazolium compound to a soluble red formazan product. First the 
substrate of the EZ4U reagents had to be dissolved at 37°C by adding 2,5ml 
activator to the substrate. Then 20µl of the reagent was pipetted per well and 
after incubation of 2,5 hours the absorbance was measured at 450nm against a 
655nm reference wavelength with a microplate reader spectrophotometer (Bio-
Rad Laboratories, Model 680). IC50 values were calculated with Excel and 
dose-response curves were designed with SigmaPlot software.           
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3.6 Protein analysis  
3.6.1 Protein extracts  
5x105 cells were seeded in 60mm tissue culture petri dish before protein 
extraction was perfomed. Every step was done on ice. The respective culture 
media was removed and the cells were washed twice with cold PBS. Then the 
remaining PBS was removed and 80µl RIPA+ (prepared as described in (Tab.1 
and 2) was added to one 60mm dish (1 confluent 60mm dish gives 150 µg 
protein).  
Tab.1: RIPA lysis buffer 
Reagent MW Stock Storage Vol 
Final 
concentration 
NaCl 58.44 5M rt* 3ml 150mM 
Tris pH 7.4 121.14 1M rt 5ml 50mM 
DOC 
(Na-deoxycholate) 414.6 10% rt (keep dark) 5ml 0.5% 
EGTA 380.4 50mM rt 4ml 2mM 
EDTA, pH 7.4 372.2 50mM rt 10ml 5mM 




216 400mM 4C 10ml 40mM 
Tetrasodium 
pyrophosph. 
446.06 100mM rt 10ml 10mM 
Benzamidine 156.6 30mM 4C 10ml 3mM 
Nonidet P-40  pure rt 1ml 1% 
*rt room temperature 
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After all components were mixed, pH was set to 7,4 and the volume was filled 
with Aqua bidest. up to 95,0 ml. The RIPA solution was stored at 4°C and 
shortly before use RIPA+ was prepared.  
Tab.2: RIPA+ lysis buffer 
RIPA+ 2ml 
RIPA 1,90ml
200mM Na-Orthovanadate 20µl 
25 x Complete stock solution 80µl 
After adding 80 µl RIPA+, cells were scraped with a sterile scrapper. Then the 
lysates were transferred to one Eppendorf tube, vortexed several times and 
spun for 30min at 12.500rpm in a microfuge at 4°C. The pellet was discarded 
and the supernatant was saved at -20°C for the protein assay.   
3.6.2 Protein quantification  
Determination of protein concentration in the samples was done with the 
BioRad Protein Assay Kit II (Cat# 500-0112). The Kit was performed in a 96-
well plate. For measurements, first a 10mg/ml bovine serum albumine (BSA) 
stock solution was produced for protein standards by dissolving, for example 
28.4mg BSA in 2.84ml Aqua bidest. This stock solution was serially diluted 1:2 
with RIPA+ to obtain 5, 2.5, 1.25, 0.625, 0.3125, 0.15625 µgBSA/µl protein 
standards (Blank was RIPA+). Then these standards were set up in the 96 well 
plate. 
Pipet after this concept: 
-pipet 5µl RIPA+ in Blank wells 
-pipet 5µl protein standards/well, triplicates 
-pipet 5µl samples/well, triplicates  
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Reagent A of the Protein Assay Kit II was prepared freshly every time by taking 
1ml Reagent A  + 20µl Reagent S.  20µl Reagent A /well and 200µl Reagent 
B/well were added. Finally, the extinction was measured at 620/450 nm in the 
microplate reader (spectrophotometer Bio-Rad) after an incubation time of 
20min. The standard curve and protein concentration were calculated using 
Excel. The samples were stored in 4x sample buffer (Tab.3) at a final 
concentration of 1µg/µl at -20°C, that means the protein sample had a 
concentration of 1,33 µg/µl before 4x sample buffer was added [e.g. 3 parts 
protein sample in RIPA+ (1,33µg/µl) + 1 part 4x sample buffer = 1 µg protein/µl].   
Tab.3: 4x sample buffer 
Reagent MW Stock Storage Volume
Final 
concentration
Glycerol 92.09 pure rt 5 ml 50% 
Tris-HCl, pH 6.8 121.14 1M rt 1.25 ml 125mM 
SDS  20% rt 2,00 ml 4% 
Bromophenol blue  1% rt 1,25 ml 0,125% 
Beta-mercaptoethanol 
(to be added just before 
use)  
pure rt 0.5ml 5% 
*rt room temperature  
3.6.3 SDS- Polyacryl amide gel electrophoresis (PAGE)  
The glass plates for PAGE were washed with Aqua bidest. and 70% ethanol 
(EtOH), the spacers only with Aqua bidest. and then assembled according to 
Bio-Rad instructions. Then the separating gel was prepared (Tab.4a and 4b). A 
7,5% gel was used, a middle solution depending on the size of proteins of 
interests.  
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Tab.4a: A/B Solution 
Reagent  Volume 
40% Acrylamid (Biorad 
#1610140)  
11,1 ml 
2%  Bis Solution (Biorad # 
1610142) 
3 ml 
Aqua bidest. 0,9 ml 
30 % A/B 15 ml  
 




30% A/B 5 ml 
Aqua dest. 9,7 ml 
1,5M Tris 8,8 5 ml 
10% SDS 200µl 
10% APS 100µl 
Temed pur 10µl 
The cassette was filled ~¾ full with separating gel (Tab.4b) and carefully 
(slowly) overlayed with some Aqua bidest. to remove any air bubbles. The 
solution polymerized for 30 45 min. Aqua bidest. was discarded off the 
cassette and the comb was inserted. The 4% stacking gel solution (Tab.4c) was 
poured to the very top, the comb slightly drawn up and the gel polymerized for 
~30min. 
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Tab.4c: 4% stacking gel 
Reagent 4% gel 
30% A/B 1,673ml 
Aqua bidest. 7,47ml 
0,5M Tris 6,8 3,15 ml 
10% SDS 125µl 
10% APS 125µl 
Temed pur 12,5µl 
The cassettes were inserted in the electrophoresis apparatus and 1x running 
buffer (25mM Tris, 192mM Glycine, 0,1% SDS in Aqua bidest.) was added. The 
protein samples were boiled for 10 min at 95°C before each use for 
denaturation and then put on ice. 20µl of the protein samples (20µg protein) and 
2 µl of the molecular weight marker (Magic Mark XP from Invitrogen) were 
loaded on the gel. The gel was run at constant 100 Volt for approximately 2 
hours. After electrophoresis, the gel was subjected to Western blotting  
3.6.4 Western blotting  
The separated proteins were transferred from the gel onto a Hybond-P 
polyvinylidene fluoride (PVDF) membrane. Before the transfer, the membrane 
had to be prewet in pure methanol. For identification cut marks in the rim of the 
PVDF (Polyscreen, NEF 1000, 153196) membranes corresponding to marks to 
be made in the rim of the gels. The blotting sandwich was assembled with the 
PVDF membrane and the gel in between as shown in Fig.12. A pipet fragment 
was used for rolling out some air bubbles that might have been formed during 
the assembly of the sandwich.    
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Fig.12: The blotting sandwich  
*PAA polyacrylamide  
The sandwich was closed with the clamp, still submerged in transfer buffer 
(150mM Glycine, 50mM Tris pH8,3, 0,05% sodium dodecylsulfate (SDS), 20% 
Methanol) in the tray. The chamber was filled with precooled transfer buffer and 
the sandwich put into the sandwich holder (black side faces black electrode), 
which was already in the chamber. The rest of transfer buffer was filled into the 
transfer chamber and the stirring rod was put inside. The electrotransfer was 
performed at constant 290mA overnight at 4°C.  
3.6.5 Immunostaining of the blot membranes  
Specific binding of the first antibody to the proteins and detection of horseradish 
peroxidise (HRP) conjugated to the secondary antibody with enhanced 
chemiluminescense (ECL-Substrat,Pierce,#32106) led to the detection of the 
proteins.  
The transfer apparatus and the blotting sandwich were disassembled and the 
blot membrane cut exactly to the size of the gel with a razor blade. First of all, 
the PVDF membrane was blocked in blocking solution (BS) with 4% FCS (see 
Tab.5a) for 1 h at room temperature. 
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Tab.5a: Immunostaining buffers part1            
Tab.5b: Immunostaining buffers part2           
The membrane was washed 3 times for 5min in TBS-T (Tab.5a) on the shaker 
and then incubated with the first antibody (Tab.5b and 6) at room temperature 
for 2 hours or overnight at 4°C. After incubation with the first antibody, the 
membrane was washed again two times for 5min and two times for 10min in 
TBS-T. In a second step the secondary antibody (Tab.5b and 7), conjugated 
HRP, was diluted in TBS-T + 1%  BSA just before use and the membrane was 
incubated for 1 hour at room temperature on the shaker. After that the 
membrane was washed 2 times for 5min, 2 times for 10min in TBST and 2 
times for 5min, 2 times for 10min in TBS (Tab.5a). For detection the membrane  
-10x Tris-buffered saline (TBS) (Biorad # 1706435): 
1x TBS: 50mM Tris pH7,5, 150mM NaCl 
-TBS-T: 
1x TBS with 0,1% Tween20  (1ml Tween20 to 1000ml TBS) 
-Blocking solution (BS): 
1x TBS-T with 4% bovine serum albumin (BSA) (4g BSA in 100ml 1x TBS-T) 
-Blocking solution (BS) + 4% FCS: 
add 800 µl FCS to 20 ml BS 
-First antibody solution: 
make 1% BSA in TBS-T: add 1 vol BS to 3 vol TBS-T 
1x TBS-T with 1% BSA and 0,05% Na-azide (20ml TBS-T  with 1% BSA + 
100µl 10% Na-azide/blot) 
-Secondary antibody solution: 
TBS-T with 1% BSA  
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was incubated with a mixture of 2ml Detection solution1 + 2ml Detection 
solution 2 (ECL-Substrate) which underwent a chemiluminescence reaction with 
the horseradish peroxidise (HRP) conjugated to the secondary antibody. The 
protein bands were visualised by exposing the membrane to a x-ray film 
(Hyperfilm ECL high performance chemiluminescence film, Amersham, 
RPN3103K).  
Tab.6: First Antibodies  




mTOR 1:1000 rabbit 
polyclonal IgG





Cell Signaling #2971 287kDa
EGFR   1:500 rabbit 
polyclonal IgG






































Cell Signaling #4754 185kDa
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pErbB-3 
(Tyr1289)   
1:1000 rabbit 
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Tab.7: Secondary antibodies 
2ndAntibody Dilution Feature Company 
Cat. 
No 










Goat-anti-rabbit   1:2000 horseradish 
peroxidase 
(HRP) linked 
Cell Signaling #7074 
3.6.6 Stripping of membranes  
For the possibility to use the blots again and to avoid background signals the 
membranes were stripped with 20ml stripping solution (Tab.8) and 200µl ß-
Mercaptoethanol per 20ml stripping solution. The blots were stripped for 20min 
at 50°C in a water-bath with frequent shaking. Before the subsequent procedure 
was followed in the regular way by blocking the blotting membranes in 
BS+4%FBS for 1 h, the blots were washed several times in TBS-T.  
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Tab.8: Stripping solution 
Reagent Quantity 
SDS    10g 
1M Tris pH6,7  31,3ml 
fill up with water to 
500ml 
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3.7 Transformation of DNA into bacteria  
3.7.1 Transformation of JM-109 (E-coli) competent cells  
A human myc-ca-Mek1/pBlueskript KS plasmid on a filter paper was generously 
provided by Hiroshi Kiyama (Inst. of Japan, Namikawa et al., 2000) and for 
efficient transfection into eukaryotic cells, the myc-tagged constitutively active 
MEK1 fragment had to be excised and cloned in pcDNA3, which represents an 
ideal expression vector for eukaryotic cell lines. 
A piece from the filter paper containing human myc-ca-MEK1/pBlueskript KS 
was cut off and dissolved in 100µl TE buffer, incubated for 2 hours at room 
temperature. Then 5µl of this solvent plasmid and pBlueskript control (kindly 
provided by Michael Grusch, Institute for Cancer Research) were added to 
100µl competent cells (JM-109, E.coli) and stored on ice for 20min. After 1 min 
heat shock at 42°C 1ml SOC medium (Tab.9) was added to the cells. Two 
hours later cells were harvested by centrifugation for 3min at 2000g and the 
supernatant was discarded. 100µl were left back and the resulting culture was 
spread out on LB (Tab.10) plates (containing 50µg/ml ampicillin) and grown 
overnight at 37°C.             
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Tab.9: SOC-medium 
Reagent Quantity 
tryptone  20g 
yeast extract 5g 
10mM NaCl 0,584g 
2,5mM KCl 0,186g 
10mM MgCl2 0,952g 
20mM glucose 3,603g 
adjust the pH to 7.0  
with sodium hydroxide 
fill up with water to 1000ml 
autoclave at 121°C for 20min 
Tab.10: LB-medium 
Reagent Quantity 
tryptone   10g 
yeast extract 5g 
NaCl 10g 
adjust the pH of LB to 7.5 or 8  
with sodium hydroxide  
fill up with water to 1000ml 
autoclave at 121°C for 20min 
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3.7.2 Plasmid isolation Miniprep Quick `n` Dirty  Boiling lysis  
A couple of eprouvettes containing 6ml LB-Broth (Sigma, L3022-1kg) with 
ampicillin (stock: 50mg/ml, Roche Art. Nr.10 835 242001, Lot 93271021) were 
inoculated with different colonies taken from the agar plate and incubated at 
37°C overnight. The next day 1.5ml of the overnight culture were transferred to 
a 1.5ml microcentrifuge tube and harvested by centrifugation for 1min at 
16000g. To increase the yield this step was repeated again. Then the medium 
is aspirated, the pellet was resuspended in 700µl STET-buffer (8% glucose, 5% 
Triton X100, 50mM EDTA and 50mM Tris pH8) and 13µl lysozyme (stock 
50µg/ml, Sigma L-7651) was added. The tube was mixed 3 times and boiled at 
100°C for 1-2min. The proteins were pelleted at 12000-16000g for 10 min and 
the pellet was discarded with an RNAse A (stock 10mg/ml, Sigma R-5503) 
covered toothpick. After adding 700µl isopropanol the plasmid DNA was 
precipitated for 20 min at -20°C and pelleted at 4°C with top speed for 
15min.The supernatant was discarded and the pellet was washed with 500µl of 
70% ethanol, and then centrifuged at room temperature with top speed for 
5min. Then the ethanol was aspirated and the step was repeated again. After 
the pellet was dry it was resuspended in 20µl TE-buffer and stored at 4°C or -
20°C.  
3.7.3 Restriction assay for control  
To control if the right colony was picked from the agar plate, a restriction assay 
was prepared in order to cut the plasmid in pieces. The use of restriction 
enzymes depends on the vector. Clone manager software was used to choose 
the right enzymes. For restriction analysis Aqua bidest. DNA and the 10xbuffer 
were prepared in a 1.5ml microcentrifuge tube and finally restriction enzymes 
were added (Tab.11).   
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Tab.11: Restriction analysis 
Probe  pBluscript 1  pBluscript 2 
DNA 1µl 1µl 





Fermentas # ER 0592 
1µl XhoI 
10U/µl, 2000U 
Fermentas # ER 0691 





Roche # 742953 
1µl BamHI 
10U/µl, 4000U 
Fermentas # ER 0051 
10xBuffer 
Company 
1µl 10x buffer BamHI 
Fermentas # B57 
1µl 10x buffer BamHI 
Fermentas # B57 
Aqua bid. 6 µl 6µl 
Sum 10µl 10µl 
The mix was incubated for at least 2 hours at 37°C. Then a 1% agarose gel 
(Biozyme LE Agarose Art Nr 840004, 500g) was poured. To detect the bands, 
10µl of the restriction mix were mixed with 2µl Vistra-Green (GE Healthcare) 
and loaded on the gel. Furthermore a marker solution consisting of 1µl Gene 
Ruler 1kb DNA ladder (Fermentas #SM1163) mixed with 9µl Aqua bidest.  and 
2µl Vistra-Green was loaded on the gel. For electroporetic seperation the gel 
was run for 1 hour at 110V in 0,5 x TBE buffer (Tab.12). Data were analyzed 
using Fluor Imager 595 Scanner (Molecular Dynamics). The obtained MEK1 
fragment had a size of 1181bp (Fig.13).         
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Tab.12: 0,5 x TBE buffer 
Reagent Quantity 
Tris    54g 
Boric acid 27,5g 
0,5ml EDTA/pH8,0 20ml 
Aqua bidest.       fill up to 10l 
3.7.4 Restriction assay for preparing vector DNA (pcDNA3) and insert 
DNA (MEK1) for ligation   
After the control on the gel 19µl of the pBluescript (left from the miniprep) 
containing the MEK1 insert (Fig.13) and a pcDNA3 vector (Fig.14), (kindly 
provided by Michael Grusch, Institute for Cancer Research) were prepared and 
cut with restriction enzymes (Tab.13) and religated.  
Fig.13: pBlueskript KS  MEK1 
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Tab.13: Restriction analysis 
Probe pBluscript MEK1 pcDNA3 
DNA 19 µl 20µl 





Roche # 742953 
3µl KpnI 
40U/µl, 10000U 
Roche # 742953 





Fermentas # ER 0051 
3µl  BamHI 
10U/µl, 4000U 
Fermentas # ER 0051 
10xBuffer  
Company 
6µl 10xbuffer BamHI 
Fermentas # ER 0051 
6µl 10xbuffer BamHI 
Fermentas # ER 0051 
Aqua bid. 29 µl 28µl 
Sum 60µl 60µl 
After incubation of the restriction mix the vector was dephosphorylated to avoid 
re-ligation by exposure to Calf Intestine Alkaline Phosphatase (CIAP), 
(Fermentas #Ef03U1). 
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Procedure:  
pCDNA3 
-pCDNA3 60µl + 1µl CIAP 
-30min 37°C 
-30min 56°C 
+ 1µl CIAP 
-30min 37°C 
-30min 56°C  
This reaction mix was incubated for 2 hours and then a 1% agarose gel was 
poured. For further experiments 60µl of the restriction mix MEK1 and 62µl of the 
dephosphorylated restriction mix pcDNA3 were mixed with 12µl Vistra-Green 
(GE Healthcare) and loaded on the gel. In addition a marker solution as 
mentioned above was loaded on the gel. For electroporetic seperation the gel 
was run for 1 hour at 110V in 0,5 x TBE buffer. Data were analyzed using the 
Fluor Imager 595 Scanner and the obtained bands of MEK1 (1181bp) and 
pcDNA3 (5446bp) were cut out of the gel and cleaned by using the Wizard SV 
Gel and PCR Clean-Up System (Promega Part #9F B072,Lot #259073, Exp. 
Date: JUL11).   
3.7.5 Ligation of pCDNA3 (vector) with Mek1 (insert)  
The gel purification was performed as described in the protocol and in addition 
2µl of each isolated fragment was loaded on a 1% agarose gel with appropriate 
amount of Vistra-Green. Gel electrophoresis was performed at 110V for 2 
hours. To figure out the concentration of vector DNA and insert DNA which 
were cut out of the gel, their quantities were calculated in relation to the 1000bp 
band of the marker. The vector DNA contained 271ng/µl and the insert DNA 
178ng/µl. For the ligation assay the data were calculated using Image Quant 5.0   
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software and after calculation of the ratio between vector and insert the 
reagents were prepared for the ligation reaction (Tab.14).  











Vector-DNA 0,5µl 0,5µl 0,5µl 
Insert-DNA 0,49µl 0,82µl 
10x T4 Ligase buffer 
Fermentas # B69 
1µl 1µl 1µl 
T4 DNA Ligase 
5U/µl, 200U,Fermentas# 
EL0014 
1µl 1µl 1µl 
Aqua bid. 7µl 6,7µl 7,5µl 
Sum 10µl 10µl 10µl 
Then the ligation mix was incubated overnight at 16°C and 5µl DNA of ligation1 
(3x surplus of insert), ligation2 (5x surplus of insert) and ligaton3 (negative 
control) were transformed in competent JM-109 (E.coli). on the next day, 12 
eprouvettes containing 6ml LB-Broth supplemented with 50µg/ml ampicillin 
were inoculated with different colonies taken from the agar plate and incubated 
at 37°C overnight. 1ml LB-Broth from each eprouvette containing transformed 
bacteria was put into the freezer for later experiments. 24 hours later a Plasmid 
Miniprep like the Quick `n` Dirty  Boiling lysis protocol above was performed.       
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3.7.6 Restriction assay after Ligation  
After plasmid isolation a restriction assay (Tab.15) was prepared to look if one 
of the 12 clones contained the right plasmid with MEK1 as insert with a size of 
1181bp.  
Tab.15: Restriction assay 
Probe Ligation 1-12 
DNA 1µl 





Roche # 742953 





Fermentas # ER 0051 
10xBuffer  
Company 
1µl 10xbuffer BamHI 
Fermentas # ER 0051 
Aqua bidest. 6 µl 
Sum 10µl 
After the mix was incubated for 2 hours at 37°C, a 1% agarose gel was 
prepared and 10µl restriction mix supplemented with 2µl Vistra-Green and the 
marker solutuion was loaded. The gel was run for 1 hour at 110V and data were 
analysed using the Fluor Imager 595 Scanner. MEK1 fragment with 1181 bp 
size was expected. One clone exhibited the right size and to convince the 
correctness of this clone a further restriction assay was performed (Tab.16).     
  
- 50 -  
Material and methods  
Tab.16: Restriction assay 
Probe  Right Clone  Right Clone 
DNA 2µl 2µl 





Fermentas# ER 0271 
0,5µl XhoI 
10U/µl, 2000U 
Fermentas # ER 0691 
10xBuffer 
Company 
1µl 10x buffer EcoRI 
Fermentas # B12 
1µl 10x buffer Red 
Fermentas # BR5 
Aqua bid. 6,5 µl 6,5µl 
Sum 10µl 10µl 
The restriction mix was incubated at 37°C for 2 hours and was then loaded on a 
1% agarose gel and bands were analyzed expecting fragments after EcoRI 
digestion of 744bp and 5940bp and after XhoI digestion fragments of 1299bp 
and 5385bp (Fig.15).   
Fig.15: EcoRI and XhoI cut 
By this transforming and cloning procedure we obtained a pcDNA3 plasmid 
containing the constitutively active MEK1 (Fig.16).   
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Fig.16: Constitutively active Mek1 in pcDNA3 





























3.7.7 PureYield Plasmid Midiprep   
After the correct clone has been obtained, 10µl from the remaining 1ml LB-
Broth was inoculated into 100ml LB-Broth containing 50µl/ml ampicillin. As well 
as the correct clone, EGFP (Institute of Cancer Research) and dominant active 
murine AKT, which was a kind of gift from D. Efremov [(International Centre for 
Genetic Engineering & Biotechnology, Monterotondo Scalo, Italy), Longo et al., 
2007] were inoculated into 100ml LB-Broth containing ampicillin. These cultures 
were incubated overnight at 37°C and isolated using PureYield Plasmid 
Midiprep System (Promega Cat # A2492). The DNA concentrations were 
calculated with Nanodrop ND-1000.     
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3.8 Transfection of DNA into eukaryontic cells   
3.8.1 Transient transfection  
One day before transfection, 8x105 SKBR3 cells were plated in 2ml culture 
medium (D-MEM supplemented with 10% FCS and 1% PSG) in 6-well plates 
(Corning Incorporated, 3506).  The cells should be 80% confluent before 
transfection. Next day, the attached cells were controlled under the microscope, 
the culture medium was removed and 2ml culture medium was added again. 
Further, the transfection sample was prepared (mix for 1 well) diluting plasmid 
DNA (Tab.17) in 400µl Opti-MEM I (Invitrogen, Cat.No. 31985-062), mixing, and 
adding 8µl Lipofectomine LTX reagent (Invitrogen, Cat.No. 15338-100) directly 
to the diluted DNA. This complex was incubated for 30min at room temperature. 
The Opti-MEM-DNA-LTX containing complex was added to the well with the 
cells and mixed gently. The cells were incubated at 37°C in a CO2 incubator for 
24 hours. To check the transfection efficiency, a EGFP plasmid was used as 
control, which was expressed in the cell 24h after the transfection. Under the 
microscope, cells appeared green. The used filter block for the microscope I 2/3 
emitted blue light. After microscopic control, the transfection complex was 
removed, and 2ml culture medium were again added.  One day later, cells were 
trypsined with 300µl 0,05% Trypsin-EDTA, counted and seeded in 96-well 
plates for EZ4U growth assays or in 60mm petri dishes for Western blot 
analysis.          
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Tab.17: Plasmid DNA 
Plasmide  Concentration  Source 
pcDNA 3 647,9ng/µl Institute of Cancer 
Research 
pcDNA3 EGFP 207,7ng/µl Instiute of Cancer Research 
pcDNA3 MEK1 533,54ng/µl  Prepared by Cloning  
pcDNA3 AKT 315,1ng/µl Dimitar Efremov Longo et 
al., 2007 
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4 Results  
4.1 EGFR/ErbB-2 receptor tyrosine kinase inhibitor 
pelitinib inhibits monolayer growth of SKBR3 but 
not of T47D breast cancer cells  
Previous studies have shown that small-molecule tyrosine kinase inhibitors 
(TKIs), such as anti-EGFR and anti-ErbB2 drugs inhibit the growth of breast 
carcinoma cell lines (Moulder et al., 2001 and Erlichman et al., 2006). Whereas 
the majority of patients with breast cancer do not respond to TKIs, due to 
intrinsic or acquired resistance (Normanno et al., 2008). 
SKBR3 and T47D human breast cancer cells proved to be sensitive and 
resistant against EGFR/ErbB-2 receptor TKI pelitinib (EKB-569), respectively. 
SKBR3 and T47D were cultured as described in Material and Methods. 
Sensitivity of SKBR3 and the resistance of T47D against pelitinib were 
demonstrated in invitro growth assays. Cells were treated for 72h with 0,1µM, 
1µM, 2µM, 4µM, 6µM, 10µM and 15µM pelitinib. SKBR3 cells, a ErbB-2 
overexpressing but estrogen receptor (ER) and progesterone receptor (PR) 
negative breast cancer cell line revealed a IC50 of 2,67µM (Fig.17). Whereas 
T47D cells, which are positive for ER and PR but do not overexpress ErbB-2 
demonstrated striking resistance against pelitinib with a four- to five-fold higher 
IC50 value (12,06µM) than SKBR3 (Fig.17).          
  
- 55 -  
Results  
                 
Fig.17: Breast cancer cell lines SKBR3 and T47D exposed to pelitinib. Cells were 
grown in 96-well plates, allowed to attach o.n. and treated for 3 days with 0,1µM, 1µM, 
2µM, 4µM, 6µM, 10µM and 15µM pelitinib. Before the absorbance was measured at 
450nm against a 655nm reference wavelength with a microplate reader 
spectrophotometer, the EZ4U reagent was added.         
Pelitinib (µM)
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4.2 ErbB receptor expression profile and downstream 
signaling in SKBR3 and T47D breast cancer cells  
To identify possible molecular parameters for sensitivity or resistance of SKBR3 
and T47D cells against pelitinib the patterns of ErbB receptor expression and of 
the downstream signaling proteins were examined by Western blot analysis 
(Fig.18). SKBR3 and T47D were plated in serum-free media. Twenty-four hours 
later protein extracts were prepared as described in Material and Methods.  
The ErbB receptor signaling pathway and its downstream signaling components 
play an important role in cell survival, cell proliferation and cell differentiation. 
ErbB-2 is overexpressed in 20-30% of human breast carcinomas and correlate 
with an aggressive behaviour and poor clinical prognosis. SKBR3 cells 
overexpress EGFR. They also exhibit a high-copy-number amplicon in the 
centromere region of chromosome 17 containing the ErbB-2 onco-gene 
providing high ErbB-2 expression (Szöllösi et al., 1995 and Shadeo et al., 
2006). We compared ErbB expression and phosphorylation in SKBR3 and 
T47D cells. In SKBR3 cells the ErbB-2 receptor appears to be constitutively 
phosphorylated whereas EGFR is not phosphorylated in the absence of growth 
factors or serum (Fig. 18). SKBR3 show low levels of ErbB-3, which is however 
highly phosphorylated. In contrast, ErbB-4 protein and phosphorylation was not 
detectable in SKBR3 by Western blotting (Fig.18). 
T47D reveal constitutive expression of all four ErbB receptors. However, the 
levels of EGFR, ErbB-2 and ErbB-3 are lower than in SKBR3 (Fig.18).  
Moreover, in contrast to SKBR3 T47D exhibit ErbB-4 receptor expression. From 
these four ErbB receptors only ErbB-2 and ErbB-3 are constitutively 
phosphorylated (Fig.18). 
In summary, SKBR3 cells express relatively high levels of EGFR, ErbB-2 and 
ErbB-3, but no ErbB-4 whereas T47D express relatively low levels of all four 
ErbB receptors. In both cell lines, constitutive activation/phosphorylation is seen 
for ErbB-2 and ErbB-3, but not for EGFR and ErbB-4. Thus, while the principal 
building of ErbB baseline signal transduction appears quite similar in the nature  
  
- 57 -  
Results  
in both cell lines emanating from ErbB-2/ErbB-3 heterodimers, the intensity 
appears higher in SKBR3 than in T47D probably due to receptor 
overexpression in the former. 
We next examined expression and baseline phosphorylation of AKT and 
ERK1/2, the crucial mediators of the PI3K and MAPK pathways, respectively 
(Fig19), which represent the two major downstream signaling cascades of ErbB 
receptors. Both AKT and ERK1/2 are expressed at similar levels in both cell 
lines. However, despite relatively high intrinsic ErbB-2/ErbB-3 activity in SKBR3, 
pAKT and pERK1/2 levels are yet markedly lower in SKBR3 when compared to 
T47D cells indicating high constitutive activation of ErbB downstream pathways 
in T47D cells.                      
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Fig.18: Total protein from SKBR3 and T47D cells were labeled with anti-EGFR, 
ErbB-2, ErbB-3, ErbB4 or anti-pEGFR, pErbB-2, pErbB-3, pErbB4 antibodies. 
Cells were allowed to attach o.n. in 5% FCS and were grown in 60 mm dishes. Medium 
was changed to medium without FCS for 24 hours. Before sample preparation the 
cultures were exposed for 6 hours to DMSO. Alpha/beta tubulin was detected for 
loading control. 
Fig.19: Total protein from SKBR3 and T47D cells were labeled with anti-AKT, 
ERK1/2 or anti-pAKT(Ser473) and pERK1/2  antibodies. Cells were allowed to 
attach o.n. in 5% FCS and were grown in 60 mm dishes. Medium was changed to 
medium without FCS for 24 hours. Before sample preparation the cultures were 
exposed for 6 hours to DMSO. Actin was detected for loading control. 
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4.3 Stimulation  of  ErbB  receptors  and  of  ErbB      
downstream    pathways by   EGF  
ErbB receptors are activated by a repertoire of ErbB ligands which include EGF, 
amphiregulin (AR) and transforming growth factor- (TGF- ), which bind to 
EGFR, and betacellulin (BTC), heparin-binding EGF (HB-EGF) and epiregulin 
(EPR) which interact with EGFR and ErbB-4. The third family of ligands is 
termed neuregulins or heregulins, which include HRG1 and HRG2 that bind to 
ErbB-3 and ErbB-4, and HRG3 and HRG4 which bind exclusively ErbB-4 
(Olayioye et al., 2000). 
Here we used EGF as a prototype ligand for stimulation of EGFR and the ErbB 
downstream pathways and compared signaling behavior in SKBR3 and T47D 
cells by using Western blotting analysis. Cells were cultured in normal growth 
medium with 5% FCS for one day and then depleted of serum for another day. 
SKBR3 and T47D cells were stimulated for 1, 2, 3, 10 or 20min with EGF. 
Antibodies against ErbB receptors or against their phosphoylated form were 
used. Actin was detected as a control for equal loading and efficient protein 
transfer on to the PVDF membranes. During the course of our studies we found 
that 2min of exposure to EGF is required to stimulate EGFR phosphorylation in 
SKBR3 (Fig.20), whereas in T47D, 1min is already sufficient to stimulate EGFR 
(Fig.21). Generally, in both cell lines EGF-mediated phosphorylation of EGFR 
and AKT is transient and returns near to baseline levels after 20min EHF 
stimulation, whereas ERK1/2 remains phosphorylated during the whole period 
of EGF exposure (Fig.20 and 12). Furthermore, ErbB-2 just as ErbB-3 is 
constitutively active and is resistant to further stimulation by EGF. Interestingly, 
ErbB receptors respond to EGF stimulation quite similarly compared to SKBR3, 
irrespective of the fact that T47D express much less ErbB receptors than 
SKBR3 (Fig.18). Moreover, in both cell lines 1min EGF stimulation is long 
enough to trigger the major ErbB controlled downstream signaling cascades, 
which is evidenced by increased levels of pAKT(Ser473), pAKT(Thr308) and 
pERK1/2 (Fig.20 and 21).  
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Fig.20: Total protein from SKBR3 cells were labeled with anti-EGFR, ErbB-2, 
ErbB-3, ErbB4, AKT, ERK1/2 or anti-pEGFR, pErbB-2, pErbB-3, pErbB4, pAKT 
(Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Medium was changed to medium without FCS 
for 24 hours. Before sample preparation the cultures were exposed for 0,1, 2, 3, 10, 
20min to recombinant human EGF(100ng/ml). Actin was detected for loading control         
  
- 61 -  
Results  
Fig.21: Total protein from T47D cells were labeled with anti-EGFR, ErbB-2, ErbB-
3, ErbB4, AKT, ERK1/2 or anti-pEGFR, pErbB-2, pErbB-3, pErbB4, pAKT 
(Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Medium was changed to medium without FCS 
for 24 hours. Before sample preparation the cultures were exposed for 0,1, 2, 3, 10, 
20min to recombinant human EGF(100ng/ml). Actin was detected for loading control.       
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4.4 The tyrosine kinase inhibitor pelitinib inhibits ErbB 
receptor signaling in SKBR3 and T47D cells 
stimulated with EGF and heregulin (HRG)  
To test the function of the irreversible EGFR/ErbB-2-dual small-molecule RTKI 
pelitinib (Wissner et al., 2008) we cultivated SKBR3 and T47D cells as 
described in Material and Methods, depleted for one day from serum and then 
treated the cells for 6 hours with 0,1µM, 1µM, 2µM, 4µM or 8µM pelitinib. 
Finally, the cells were stimulated with 3min with EGF and heregulin ß1 
(HRGß1). Results were then detected by western blotting analysis. Alpha/beta 
tubulin was used as loading control. First it was demonstrated that EGFR and 
the ErbB-3 are activated by EGF and HRGß1 stimulation in both SKBR3 and 
T47D cells (Fig.22 and 23). It has to be mentioned that ErbB-3 not only 
requires ligand for activation, but also has to form a heterodimer with one of the 
other ErbB receptors. For instance, cross talk between ErbB-3 and ErbB-2 
triggers a very strong signaling cascade although each alone represents an 
invalid receptor. ErbB-2 lacks a cognate ligand and thus does not function as a 
receptor in the classical meaning domain, whereas ErbB-3 lacks functional 
tyrosine kinase. Nevertheless, these receptors complement each other and 
cooperate during signaling. In SKBR3 it is not possible to activate ErbB-2 
because it is already maximally active even in the absence of ligands (Fig.22). 
Interestingly, pretreatment for 6 hours with concentrations as low as 0,1µM of 
pelitinib depresses pEGFR,pErbB-2 and pErbB-3 levels already below those 
seen without ligands. ErbB-2 is constitutively active in both cell lines and 
requires relatively high concentrations of pelitinib for inhibition which was 
accompanied by reduced steady-state levels of ErbB-2 protein.      
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Fig.22: Breast cancer cell line SKBR3 is exposed to anti-EGFR, ErbB-2, ErbB-3, 
ErbB4, AKT, ERK1/2 or anti-pEGFR, pErbB-2, pErbB-3, pErbB4, pAKT 
(Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Medium was changed to medium without FCS 
for 24 hours. The cultures were treated with 0,1µM, 1µM, 2µM, 4µM and 8µM pelitinib 
for 6 hours. Before sample preparation the cultures were exposed for 3min to 
recombinant human EGF(100ng/ml) and to heregulin ß1 (1nM). Alpha/beta tubulin was 
detected for loading control.          
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Fig.23: Breast cancer cell line T47D is exposed to anti-EGFR, ErbB-2, ErbB-3, 
ErbB4, AKT, ERK1/2 or anti-pEGFR, pErbB-2, pErbB-3, pErbB4, pAKT 
(Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Medium was changed to medium without FCS 
for 24 hours. The cultures were treated with 0,1µM, 1µM, 2µM, 4µM and 8µM pelitinib 
for 6 hours. Before sample preparation the cultures were exposed for 3min to 
recombinant human EGF(100ng/ml) and to heregulin ß1 (1nM). Alpha/beta tubulin was 
detected for loading control.          
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4.5 The effects of pelitinib on ErbB downstream 
signaling in SKBR3 and T47D cells by pelitinib 
4.5.1 In the presence of serum supplementation  
ErbB family reseptors signal via mitigen-activated protein kinase (MAPK) and 
phosphatidylinositol-3kinase (PI3K)/AKT cascades. AKT is a serine/threonine 
kinase also known as protein kinase B (PKB). Activated AKT plays a crucial role 
in progression of various breast carcinomas and can cause intrinsic or aquired 
drug resistance, including endocrine resistance (Tokunaga et al., 2006). In 
SKBR3 and T47D which proved to be sensitive and resistant against the ErbB 
TKI pelitinib, respectively, we demonstrated significant differences in 
downstream signaling. The cells were cultivated as described, cultivated for one 
day in medium containing 5% FCS and then treated for 6 hours with 0,1µM, 
1µM, 2µM, 4µM and 8µM pelitinib following by Western blotting analyses. Actin 
was used as loading control. In SKBR3, which were growth inhibited by pelitinib 
(Fig.17), the drug completely abrogated of AKT phosphorylation at serine 473 
and threonine 308 at a concentration as low as 0,1µM (Fig.24). In contrast 
T47D, cells are not growth inhibited by pelitinib and do not show reduced pAKT 
(Ser473) and pAKT (Thr308) levels upon pelitinib treatment (Fig.25). 
Interestingly, pERK1/2 was inhibited by pelitinib in both cell lines irrespective of 
growth sensitivity or resistance to the drug.  
Previous studies have demonstrated that constitutive activation of AKT could be 
caused by a deletion or mutation of PTEN, a protein and lipid phosphatase (Wu 
et al., 1998 and Dahia et al., 1999).  Loss of PTEN, associated with ErbB 
overexpression means that PI3K-mediated signaling is hyperactive. Therefore, 
we examined the PTEN status in both cell lines and show that both. SKBR3 and 
T47D, maintain PTEN expression independent of pelitinib treatment (Figs.24 
and 25).   
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Fig.24: Total protein from SKBR3 cells were labeled with PTEN, anti-AKT, ERK1/2 
or anti-pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach 
o.n. in 5% FCS and were grown in 60 mm dishes. Before sample preparation the 
cultures were treated with 0,1µM, 1µM, 2µM, 4µM and 8µM pelitinib for 6 hours. Actin 
was detected for loading control. 
Fig.25: Total protein from T47D cells were labeled with anti-AKT, ERK1/2 or anti-
pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 
5% FCS and were grown in 60 mm dishes. The cultures were treated with 0,1µM, 1µM, 
2µM, 4µM and 8µM pelitinib for 6 hours before sample preparation. Actin was detected 
for loading control. 
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4.5.2 In the presence of serum supplementation and exogenous EGF   
To examine where this inhibitor-resistant AKT phosphorylation in T47D comes 
from we raised AKT phosphorylation by exposure of the cells to EGF. SKBR3 
and T47D were cultivated for one day in 5% FCS then pelitinib was added for 
another 6 hours followed by 20min of EGF stimulation, which significantly 
activated phosphorylation of AKT and ERK1/2 in both cell lines (data not 
shown), respectively. Treatment with pelitinib inhibits the EGF stimulus in 
SKBR3 and T47D. However, in T47D a marked baseline level of AKT 
phosphorylation triggered at serine 473 and threonine 308 persisted even at 
high doses of pelitinib stimulation, whereas in SKBR3 phosphorylation of both 
amino acids is completely inhibited by pelitinib even at the lowest concentration 
tested (0,1µM, Figs.26 and 27). Baseline phosphorylation of AKT at serine 473 
and threonine 308 can be caused by activating mutations in AKT or in PI3K. 
Another possibility is that T47D produces non EGF-like autocrine factors 
(Nicholson et al., 2003) that cooperate with exogenous growth and survival 
factors present in the fetal calf serum thus maintaining high levels of AKT 
phosphorylation. Again phosphorylation of ERK1/2 is completely blocked by 
pelitinib pretreatment and can not be reactivated by EGF exposure in either cell 
line irrespective of pelitinib growth sensitivity or resistance (Figs.26 and 27).            
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Fig.26: Total protein from SKBR3 cells were labeled with anti-AKT, ERK1/2 or 
anti-pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach 
o.n. in 5% FCS and were grown in 60 mm dishes. The cultures were treated with 
0,1µM, 1µM, 2µM, 4µM and 8µM pelitinib for 6 hours. Before sample preparation the 
cultures were exposed for 20min to recombinant human EGF (100ng/ml). Actin was 
detected for loading control. 
Fig.27: Total protein from T47D cells were labeled with anti-AKT, ERK1/2 or anti-
pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 
5% FCS and were grown in 60 mm dishes. The cultures were treated with 0,1µM, 1µM, 
2µM, 4µM and 8µM pelitinib for 6 hours. Before sample preparation the cultures were 
exposed for 20min to recombinant human EGF (100ng/ml). Actin was detected for 
loading control. 
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4.5.3 In the absence of serum supplementation   
To eliminate possible effects of 5% FCS Western blot experiments were 
performed without serum. SKBR3 and T47D were cultivated as described in 
Material and Methods, depleted for one day of serum and then treated for 6 
hours with 0,1µM, 1µM, 2µM, 4µM and 8µM pelitinib. Subsequently, both cell 
lines were stimulated for 20 min with EGF. Actin was used as loading control. 
As expected, EGF stimulates AKT and ERK1/2 phosphorylation in both cell 
lines. Pelitinib completely abrogates EGF-mediated phosphorylation of AKT in 
drug sensitive SKBR3 cells, whereas in drug-resistant T47D a low baseline 
phosphorylation of AKT persists even in the absence of serum (Figs.28 and 
29). This residual, ErbB-independent-AKT activity could come from autocrine 
production of growth and survival factors in T47D cells that lead signals into the 
PI3K/AKT pathway or from intrinsic activity of the PI3K, which harbors an 
activating point mutation in the p110 alpha catalytic subunit (PIK3CA H1047R) 
in T47D cells (She et al., 2008).                
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Fig.28: Total protein from SKBR3 cells were labeled with anti-AKT, ERK1/2 or 
anti-pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach 
o.n. in 5% FCS and were grown in 60 mm dishes. Medium was changed to medium 
without FCS for 24 hours. The cultures were treated with 0,1µM, 1µM, 2µM, 4µM and 
8µM pelitinib for 6 hours. Before sample preparation the cultures were exposed for 
20min to recombinant human EGF (100ng/ml). Actin was detected for loading control. 
Fig.29: Total protein from T47D cells were labeled with anti-AKT, ERK1/2 or anti-
pAKT (Ser473/Thr308) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 
5% FCS and were grown in 60 mm dishes. Medium was changed to medium without 
FCS for 24 hours. The cultures were treated with 0,1µM, 1µM, 2µM, 4µM and 8µM 
pelitinib for 6 hours. Before sample preparation the cultures were exposed for 20min to 
recombinant human EGF (100ng/ml). Actin was detected for loading control. 
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4.6 The effect of pelitinib on AKT and ERK1/2 activity in 
pelitinib sensitive and pelitinib resistant ovarian 
cancer cells   
We next determined the growth inhibitory effect of pelitinib in a panel of ovarian 
cancer cell lines and found various degrees of sensitivity. For instance, SKOV3 
cells revealed an IC50 of 7,3 ± 0,9µM, whereas CaOV3 are highly resistant to 
pelitinib showing an IC50 fo 11.5 ± 1,3µM (data not shown). In these two cell 
lines, the effect of pelitinib on AKT and ERK1/2 phosphorylation was also 
examined. The cells were cultivated in the absence ore presence of serum as 
described in Material and Methods, treated for 6 hours with pelitinib, then 
stimulated for 20min with EGF (100ng/ml), and subjected to Western blot 
analysis. Fig. 31 demonstrates that AKT phosphorylation decreases even below 
constitutive levels seen in the absence of EGF and serum with increasing 
pelitinib concentration. In contrast, in CaOV3 cells, pelitinib concentrations as 
high as 8µM are not able to depress AKT phosphorylation below baseline levels 
seen in the absence of EGF and serum (Fig.30). Unlike AKT, ERK1/2 
phosphorylation is blocked by pelitinib below baseline levels in both cell lines, 
irrespective of their sensitivity against pelitinib in growth assays. These data 
indicates that the efficiency of pelitinib to silence AKT activity is a crucial 
parameter for growth inhibitory activity of the compound not only in breast but 
also in ovarian cancer cells.          
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Fig.30: Total protein from CaOV3 cells were labeled with anti-AKT, ERK1/2 or 
anti-pAKT (Ser473) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Lane1 exhibits cells exposed to medium 
without FCS for 24 hours, the same with lane2 but exposed 20 min to recombinant 
human EGF (100ng/ml). The cell cultures in lane3 had medium supplemented with 5% 
FCS, the same with lane4 but also exposed to 20min EGF. The cultures in lane5-10 
were treated with 0,1µM, 1µM, 2µM, 4µM, 8µM and 16µM pelitinib for 6 hours in 
medium with 5% FCS and exposed to 20min EGF. Actin was detected for loading 
control.                
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Fig.31: Total protein from SKOV3 cells were labeled with anti-AKT, ERK1/2 or 
anti-pAKT (Ser473) and pERK1/2 antibodies. Cells were allowed to attach o.n. in 5% 
FCS and were grown in 60 mm dishes. Lane1 exhibits cells exposed to medium 
without FCS for 24 hours, the same with lane2 but exposed 20 min to recombinant 
human EGF (100ng/ml). The cell cultures in lane3 had medium supplemented with 5% 
FCS, the same with lane4 but also exposed to 20min EGF. The cultures in lane5-10 
were treated with 0,1µM, 1µM, 2µM, 4µM, 8µM and 16µM pelitinib for 6 hours in 
medium with 5% FCS and exposed to 20min EGF. Actin was detected for loading 
control.          
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4.7 The effects of constitutively active, exogenous 
MEK1 and AKT1 on pelitinib-mediated growth 
inhibition in SKBR3 breast cancer cells  
ErbB receptors, especially ErbB-2, are overexpressed and hyperactivated in 
many breast cancer cells including SKBR3, and correlate with an aggressive 
clinical phenotype and unfavorable prognosis. However, EGFR, ErbB-2 and 
ErbB-3 hyperactivity (Fig.18) in SKBR3 is efficiently blocked by the dual 
EGFR/ErbB-2 targeting drug pelitinib. Correspondingly, pelitinib also inhibits 
invitro monolayer growth of SKBR3 cells (Fig.17). This correlates with pelitinib 
dependent reduction of pAKT levels in SKBR3 cells. T47D cells, while showing 
pelitinib-mediated reduction of ErbB activity, do neither reveal down regulation 
of pAKT nor inhibition of invitro growth. In contrast, to that, both pelitinib-
sensitive SKBR3 and pelitinib-resistant T47D reveal pelitinib-mediated blockade 
of ERK1/2 signaling. Moreover, a quite similar situation was found in ovarian 
cancer cells. In order to specifically examine the relative contribution of MAPK 
or PI3K/AKT signaling development of pelitinib- resistance, SKBR3 were 
transfected with either constitutively active MEK1 or constitutively active AKT1 
and the effect of pelitinib on the growth of these transfectants was examined. 
(Fig.32). AKT promotes survival of cancer cells and is often associated with 
resistance of chemo- (Clark et al., 2002 and LoPiccolo et al., 2007) radio- or 
hormone therapy (Tokunaga et al., 2006). On the other hand, the MAPK 
signaling pathway may play an essential role in developing resistance against 
tyrosine kinase inhibitors (Normanno et al., 2006 and 2008). Our data 
demonstrates that hyperactivation of the PI3K/AKT pathway by introduction of 
dominant active AKT1 markedly elevates the IC50 of SKBR3 cells to 
approximately 3,4µM, whereas hyperactive MAPK signaling due to exogenous 
MEK1 activity does not significantly change the IC50 for SKBR3 invitro growth 
(IC50 = 1,7µM) (Fig.32). Thus AKT, but not MAPK signaling essentially 
contributes to pelitinib resistance.  
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Fig.32: Transfected breast cancer cell lines SKBR3 exposed to pelitinib. SKBR3 
cells were transfected with pcDNA3, constitutively active AKT1 and constitutively active 
MEK1. Cells were grown in 96-well plates, allowed to attach o.n. and treated for 3 days 
with 0,1µM, 1µM, 2µM, 4µM pelitinib. Before the absorbance was measured at 450nm 
against a 655nm reference wavelength with a microplate reader spectrophotometer, 
the EZ4U reagent was added.         
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4.8 The effects of constitutively active, exogenous 
MEK1 and AKT1 on the activation of downstream 
signaling cascades in SKBR3 breast cancer cells 
and their responsiveness to pelitinib  
Transient overexpression and hyperactivation of MEK1, AKT1 and downstream 
signal mediators were checked by Western blot analysisSKBR3 were 
transfected as described and treated for 8 hours with 0,1µM pelitinib (Fig.33). 
Alpha/beta tubulin was used as loading control. Using antibodies against 
MEK1/2 and AKT we could confirm effective MEK1 and AKT transfection. 
Activation of MEK1 downstream signaling was demonstrated with pERK1/2 
antibody. ERK1/2 was phosphorylated in untreated wild type and all transfected 
cell lines. However, highest level of phosphorylation was seen in untreated 
MEK1 transfectants, which is resistant to pelitinib-mediated silencing (Fig.33). 
Furthermore, using a pAKT (Ser473) antibody, we demonstrated that pelitinib 
inhibits pAKT in untransfected, vector-transfected and MEK1 transfected, but 
not in AKT transfected, SKBR3 cells, which reveal strongly elevated AKT 
phosphorylation. These data suggest that the AKT pathway contributes to 
resistance of the cells against pelitinib. Moreover, AKT is known to 
phosphorylate glycogen synthase kinase (GSK)-3ß, thereby inhibiting it and 
enabling cell cycle progression by stabilizing cyclin D1 expression. Phospho-
GSK3-ß is highest in untreated AKT transfectants and is reduced by pelitinib in 
wildtype and all transfected SKBR3 cell lines. However, pelitinib-mediated 
blockade of GSK3-ß phosphorylation is markedly less pronounced in SKBR3 
expressing constitutively active AKT1 suggesting a lower efficacy of pelitinib to 
block cell cycle progression in cells transfected with AKT1 (Fig.33). 
Another downstream substrate of AKT is mTOR which phosphorylates S6 
kinase. The S6 kinase activates the ribosomal protein S6 promoting increased 
protein translation. Unexpectedly, pelitinib inhibits mTOR phosphorylation in all 
cell lines tested, including AKT1 transfectants. In contrast, while pelitinib inhibits  
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phosphorylation of S6 in wildtype, vector transfected and MEK1 transfected 
SKBR3 cells, it can only partially block S6 phosphorylation in AKT1 transfected 
cells (Fig.33). This data demonstrates that forced expression of dominant active 
MEK1 and AKT1 effectively activate the MAPK and PI3K/AKT pathways in 
SKBR3 cells, respectively, and renders them partially resistant to pelitinib. 
Moreover, we have shown that PI3K/AKT, but not MAPK hyperactivation, 
markedly contributes to resistance of the cells against the growth- inhibitory 
effect of pelitinib.  
Fig.33: Transfected breast cancer cell lines SKBR3 exposed to pelitinib. Cells 
were grown in 60mm dishes, allowed to attach o.n. and then transfected with pcDNA3, 
constitutively active AKT1 and constitutively active MEK1. After 24 hours culture was 
treated 8 hours with 0,1µM pelitinib or with DMSO.      
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5 Discussion  
ErbB receptors are associated with the development of aggressive solid tumors 
via the phosohoinositide 3-kinase (PI3K) and the mitogen-activated protein 
(MAP) kinase (MAPK) signaling pathways and are therefore important targets 
for anti-cancer therapies (Aifa et al., 2008).  The family of ErbB receptor 
tyrosine kinases consists of four homologous members (ErbB-1/HER-1/EGFR, 
ErbB-2/HER-2/Neu, ErbB-3/HER-3 and ErbB-4/HER-4) whose signaling is 
mediated through ligand binding, which triggers enhanced network signaling 
(Monilola et al., 2000; Schessinger, 2000 and Yarden et al., 2001). EGFR and 
ErbB-2 tyrosine kinase receptors are often overexpressed in breast cancer, 
promote solid tumor growth and provide perfect targets for anti-cancer therapies 
(Nicholson et al., 2001 and Ginestier et al. 2007). Elevated levels of ErbB-2 are 
associated with aggressive clinical phenotypes and poor prognosis, therefore 
representing a perfect therapeutic target for trastuzumab, a recombinant 
humanized monoclonal anti-ErbB-2 antibody (Kumar Pal et al., 2007). 
Moreover, patients with ErbB-2 overexpression can benefit from therapy with 
trastuszumab, alone or in combination with other drugs, however not all patients 
respond to these therapies dependent on development of resistance against 
trastuzumab (Nahta et al., 2006). Furthermore, Sithanandam et al., (2008) 
reported ErbB-3 involvement to be responsible for escape from therapies 
targeting other ErbB`s and as a consequence the role of ErbB-3 in breast 
cancer development has to be revealed. ErbB-4 overexpression in breast 
cancer and the reports about biological and prognostic relevance have been 
contradictory compared to the other ErbB family members (Sundvall et al., 
2008). These ErbB receptors activate signaling cascades, stimulate the PI3K 
and the MAPK and thereby control cell proliferation, differentiation, migration 
and tumor angiogenesis. Further signaling cascades are reviewed by Li et al., 
(2002) and concern the activation of signal transducers and activators of 
transcription (STAT) proteins by ErbB receptors. As a consequence, EGFR and 
ErbB-2 are the main molecular targets for cancer therapies because their  
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heterodimerization and cross talk longs for improved agents that collectively 
inhibit these two receptors (Reid et al., 2007).  
5.1 ErbB receptor profile  
In this thesis the effects of an irreversible dual EGFR/ErbB-2 inhibitor pelitinib 
(EKB-569) were assessed (Erlichman et al., 2006). Pelitinib is a small-molecule 
RTKI that competes with ATP and inhibit the tyrosine kinase domain (Wissner 
et al., 2008). This drug retains inhibitory effects against tumors which have 
become resistant against certain first generation RTKIs such as erlotinib 
(tarceva) and gefitinib (iressa), two selective inhibitors against the EGFR 
tyrosine kinase domain. We used two different breast cancer cell lines, SKBR3 
and T47D, which proved to be sensitive or resistant to the dual EGFR/ErbB-2 
inhibitor pelitinib, respectively. In the first step we performed growth assays to 
determine the antiproliferative efficacy of pelitinib. T47D exhibited an IC50 value 
that was 4,5 fold higher than that of SKBR3. Thus, pelitinib inhibited growth in 
SKBR3 cells, but not in T47D cells. We compared ErbB receptor expression 
levels in these two breast carcinoma cell lines. SKBR3 and T47D express 
EGFR, ErbB-2 and ErbB-3 whereas ErbB-4 was only found in T47D. SKBR3 
cells showed higher levels of EGFR and ErbB-2 protein expression than T47D. 
However, phosphorylation of downstream signaling proteins like AKT and 
Erk1/2 is similar in both cell lines. To test the functionality of the EGFR signaling 
pathway, SKBR3 and T47D were stimulated with 100ng/ml EGF. Both cell lines 
are responsive to EGF challenge, resulting in the formation of active EGFR 
homodimers, or EGFR/ErbB-2 and EGFR/ErBB-3 heterodimers and subsequent 
cross-phosphorylation at their tyrosine residues (Citri et al., 2006) and 
downstream activation of PI3K/AKT and ERK1/2 signaling pathways.       
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5.2 The functionality of pelitinib (EKB-569)  
Remarkable was the overexpression of EGFR and ErbB-2 in SKBR3 cells. A 
number of previous studies have successfully demonstrated inhibition of ErbB-2 
and its downstream signaling using not only antibodies such as trastuzumab 
(Moasser et al., 2001 and Anido et al., 2003), but also EGFR TKIs such as 
erlotinib and gefitinib. Other studies, however, reported EGFR tyrosine kinase 
inhibitors such as AG1478 (Grunt et al., 2007a) or gefitinib (Grunt et al., 2007b) 
already weakly effective against breast cancer cells due to release of autocrine 
ligands, such as heregulin and betacellulin, that stimulate ErbB-3 receptor and 
ErbB-4 (Kong et al., 2008). ErbB-2 can escape EGFR TKI blockade by 
formation and activation of heterodimers containing autocrine-ligand activated 
ErbB-3 and ErbB-4 receptors. We first examined functionality of the whole ErbB 
system in SKBR3 and T47D cells, by maximally stimulating it with EGF and 
heregulin (Bazley et al., 2005). EGF directly binds EGFR, but not ErbB2-4, 
whereas heregulin binds ErbB-3 and ErbB4. ErbB-2 has no known ligand and is 
only activated by heterodimerisation wit other ErbB receptors. Thus, by 
combining EGF with heregulin, we could activate the whole ErbB system in both 
cell lines. We assessed pelitinib-mediated inhibition of phosphorylation of 
EGFR, ErbB-2 and ErbB-3 in sensitive SKBR3 as well as in resistant T47D 
cells. Interestingly, in SKBR3 MAPK and PI3K/AKT downstream signaling was 
completely blocked by pelitinib, whereas in T47D AKT phosphorylation 
remained active despite inhibition of upstream ErbB receptor activation by 
pelitinib. Our data indicates that pelitinib is not only a functional inhibitor of 
EGFR and ErbB-2, but also prevents further heterodimerisation with other ErbB 
members. Our results are not consistent with the possibility that pelitinib 
resistance may be caused by lateral escape from the drug-mediated blockade 
due to compensatory formation and activation of ErbB-3 and ErbB-4 homo- or 
heterodimers in pelitinib-resistant T47D cells. However, alterations in 
downstream signaling cascades or involvement of non-ErbB are still possible 
causes for the observed resistance of T47D cells. 
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5.3 The role of the PI3K/AKT signaling pathway in 
determing cellular resistance against pelitinib  
Using Western bot analysis we were able to demonstrate differences in AKT 
(protein kinase B) signaling between SKBR3 and T47D exposed to pelitinib. 
Protein kinase B/AKT is activated by PI3K-PDK1 (Vanhaesebroeck et al., 2000) 
regulates cell survival and is therefore associated with tumorigenesis (Testa et 
al., 2001 and Nicholson et al., 2002). Moreover, PI3K/AKT pathway activation 
was revealed in breast cancer by Tokunaga et al. (2006), and is associated with 
endocrine resistance in metastatic breast cancer. T47D, representing the 
pelitinib resistant breast cancer cell line, exhibited high basal level of AKT 
phosphorylation, irrespective of pelitinib exposure. This situation is already seen 
in two different ovarian cancer cells such as SKOV3 and CaOV3, where 
differences in AKT signaling are already seen, and abrogates the possibility of 
involvement of AKT being a resistance factor against TKIs not only in breast 
cancer, but also in ovarian cancer. 
Nicholson et al. (2003) described the role of AKT and its constitutive activation. 
In SKBR3 cells, it is associated with ErbB-2 receptor overexpression, whereas 
in T47D on released autocrine factors, which act through EGFR and ErbB-2 and 
induce the AKT signaling pathway. In the presence of serum, phosphorylation of 
AKT was completely non-responsive to pelitinib and persisted at high level in 
T47D. Nevertheless, EGF still was able to elevate AKT phosphorylation even 
higher. Interestingly, this portion of AKT phosphorylation was inhibited by 
pelitinib even in the pelitinib-resistant T47D. The residual AKT phosphorylation 
could be caused by serum factors, unrelated to the ErbB system, from 
autrocrine non-ErbB growth factors or from intrinsic upstream activation through 
PI3K. Serum growth factors were mostly not involved, because removal of 
serum from the culture did not alter the overall pattern of AKT phosphorylation 
after pelitinib exposure, indicating that residual AKT activation may be either 
due to autocrine non-ErbB growth factors or due to constitutive upstream 
signaling activity. 
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Regarding multidrug resistance in breast cancer cells, Knueferman et al. 
reported involvement of ErbB-2/PI3K/AKT activation by transforming MCF-7 
cells with a dominant negative form of PI3K and AKT obtaining abrupt sensitivity 
against chemotherapeutics. According to our results, pelitinib sensitive SKBR3 
remained resistant after transfection with the constitutive active myr-AKT1 
plasmid suggesting involvement of AKT in achievement of the resistant 
phenotype. After performing Western blot analysis of transfected SKBR3 further 
supported this notion and revealed hyperactive AKT downstream signaling as 
demonstrated by elevated levels of pGSK3ß, a cell cycle regulator, and of 
phospho-S6 ribosomal protein, which is involved in protein translation.   
It was found that 26% of breast cancer cell lines exhibit a mutation in the 
catalytic subunit p110 of the PI3K (PIK3CA), an early event in development of 
the disease (Saal et al., 2005). These authors report that PIK3CA mutations are 
associated with PTEN functionality, ErbB-2 overexpression and with tumors 
exhibiting estrogen and progesterone receptors. PTEN is frequently seen in 
estrogen and progesterone receptor negative breast cancer suggesting new 
possibilities of molecular targeting anti-cancer strategies. In these cases, the 
PI3K/AKT pathway plays a pivotal role. SKBR3 cells are estrogen and 
progesterone receptor negative and overexpress ErbB-2, whereas T47D cells 
are positive for both receptors and do not overexpress ErbB-2. Consistent with 
this, T47D in contrast to SKBR3, exhibited basal phosphorylation of AKT 
despite pelitinib treatment. Consequently, pelitinib inhibited growth of SKBR3, 
lacking a PIK3CA mutation, but not of T47D cells, which exhibit a PIK3CA 
H1047R mutation. These data suggest important roles of PIK3CA mutations 
and hormone receptor pathways. Moreover, She et al. (2008) underline the 
notion that ErbB-2 amplification or PI3K mutations activate the PI3K/AKT 
pathway in breast cancer. Apart from PIK3CA mutation it was reported that 
T47D also exhibits a functional p110ß (PIK3CB) and both isoforms must be 
inhibited to completely inactivate AKT (Crowder et al., 2009). The latter report 
also demonstrates the relevance of blocking the estrogen receptor in estrogen 
receptor-positive breast cancer cells and inhibiting both PI3K p110 and p110ß 
subunits. These studies implicate the importance of PI3K/AKT signaling and its  
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role in breast cancer development. Interestingly, another group reported that 
PIK3CA mutation is correlated with PTEN loss in estrogen receptor positive 
breast cancer cell lines with no ErbB-2 overexpression, which is not associated 
with pAKT signaling suggesting that PI3K signals via other pathways that do not 
involve AKT (Pèrez-Tenorio et al., 2007).   
5.4 The role of MAPK signaling pathway in determining 
cellular resistance against pelitinib  
Similar to the PI3K/PTEN/AKT signaling pathway, the RAF/MEK/ERK MAPK 
cascades can also generate tumor development and drug resistance 
(McCubrey et al., 2006). Moreover, Moelling et al. (2002) demonstrated 
crosstalk regulation between RAF and AKT in the breast carcinoma cell line 
MCF-7. When the RAF/MEK/ERK pathway is activated it correlates with cell 
differentiation and rapid cell growth. We have explored the role of MAPK 
signaling in pelitinib resistance by transfecting pelitinib sensitive SKBR3 with a 
constitutive active MEK1 plasmid. To examine possible resistance development 
dependent on MAPK signaling, growth assays and Western blot analysis were 
performed. As expected, constitutive MEK1 transfection did not render SKBR3 
resistant against pelitinib suggesting that the relevant resistant mechanisms are 
located in the PI3K/AKT rather than in the MAPK pathway. In contrast, Magne 
et al., (2002) showed development of resistance in head and neck cancer 
against the EGFR-TKI gefitinib (iressa, ZD1839) to be dependent on MAPK 
signaling. Moreover, overcoming resistance in non-small cell lung cancer 
(NSCLC) was only achieved with EGFR-TKIs such as gefitinib associated with 
combinatory inhibition of PI3K/AKT or MAPK signaling pathways (Janmaat et 
al., 2003). Interestingly, in contrast to our data Normanno et al., (2006 and 
2008) examined acquired resistance against gefitinib in long-term gefitinib-
treated SKBR3 and associated loss of sensitivity with upregulation of the MAPK 
signaling pathway. 
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5.5 The role of IGFR signaling pathway  
The insulin-like growth factors (IGFs) bind two ligands, IGF1 and IGF2, consist 
of two cell surface receptors, such as IGF-1R and IGF-2R which mediate cell 
proliferation and inhibition of apoptosis. Upon ligand binding, the kinase is 
activated and recruits signaling molecules such as Src homology 2 containing-
domain (Shc) protein and insulin receptor substrates (IRS1-4) to the 
phosphorylated kinase domain and signals via the MAPK and the PI3K 
signaling pathway. The body-wide expression of IGF-1R and its contribution to 
growth makes the development of drugs targeting this receptor unavoidable. 
Moreover, IGF-1R expression in breast cancer is associated with hormone 
receptor expression (Hartog et al., (2007). Nowadays, IGF-1R monoclonal 
antibodies and TKIs are in early clinical and preclinical development. 
Furthermore, previous studies described involvement of IGF-1R in development 
of resistance mechanisms. Nahta et al. (2005) reported possible `cross talk` 
mechanisms between the ErbB-2 and the IGF receptors in SKBR3 breast 
cancer cells. Many ErbB-2 positive breast cancer patients receiving the 
monoclonal ErbB-2 neutralizing, growth inhibiting antibody trastuzumab 
(herceptin) developed resistance and experienced disease progression within 
several months. However, Nahta et al. (2007) reported in trastuzumab resistant 
SKBR3, that apoptosis can again be induced in these cells by treatment with 
lapatinib (GW572016) a small molecular inhibitor of EGFR and ErbB-2 and 
subsequent inhibition of IGF-1R. Consequently, in order to assess the role of 
IGF-1R signaling in pelitinib resistance, we treated SKBR3 and T47D cells with 
the IGF-1R tyrosine kinase inhibitor picropodophyllin (PPP) (data not shown). 
Interestingly, PPP had no inhibitory effects on downstream signaling, but 
instead activated AKT phosphorylation in T47D cells. This data suggests that 
IGF-1R signaling to AKT is not the cause for the observed pelitinib-resistant 
elevated basal level of constitutive AKT phosphorylation. Therefore, IGF-1R 
appears not to be involved in pelitinib resistance of T47D cells. These 
hypotheses must be scrutinized in continuative experiments. 
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6 Conclusion  
Our results dealt with the relationship between ErbB RTK mediated signaling 
pathways and the development of resistance mechanisms against ErbB RTK`s. 
We compared two breast cancer cell lines, SKBR3, which proved to be 
sensitive and T47D, which is resistant against the dual EGFR/ErbB-2 inhibitor 
pelitinib. Functional ErbB signaling mediated through EGF and heregulin ligand 
binding was assessed in both cell lines. Moreover, the ability of EGF to bind its 
receptors increased the level of activated AKT and MAPK downstream 
signaling. In addition, treatment of SKBR3 and T47D with pelitinib decreased 
phosphorylation levels of EGFR, ErbB-2 and ErbB-3 in both cell lines. 
Interestingly, downstream signaling via AKT was only inhibited in SKBR3, but 
not in T47D. Furthermore, pelitinib completely inhibited MAPK activation in both 
cell lines. To reveal the mechanisms of pelitinib resistance in T47D we 
transfected pelitinib sensitive SKBR3 either with a constitutive active myr-AKT1 
plasmid or with a constitutive active MEK1 plasmid, respectively. Interestingly, 
SKBR3 transfection with the constitutive active AKT1 but not with the 
constitutive MEK1 plasmid rendered SKBR3 resistant against pelitinib. These 
findings demonstrate the relevance of AKT signaling in contrast to MAPK 
signaling in development of resistance mechanisms against pelitinib and 
suggest that AKT should be cotargeted in order to overcome ErbB RTKI 
resistance in breast cancer cells.          
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7 Abstract  
Breast cancer already occurs in women for a long time and ErbB receptor 
tyrosine kinases are associated with its pathogenesis. This family consists of 
four homologous members: ErbB-1/HER-1/EGFR, ErbB-2/HER-2/Neu, ErbB-
3/HER-3 and ErbB-4/HER-4. In breast cancer, as well in ovarian cancer, EGFR 
and ErbB-2 receptors are overexpressed. They stimulate carcinogenesis and 
correlate with a more aggressive clinical behavior and poor prognosis. EGFR 
and ErbB-2 overexpression therefore serve as perfect targets for therapeutic 
agents. 
Our studies focused on SKBR3 and T47D human breast cancer cells which 
proved to be sensitive and resistant against the particular Epidermal Growth 
Factor Receptor (EGFR)/ErbB-2 receptor tyrosine kinase inhibitor pelitinib 
(EKB-569, Wyeth). This novel irreversible ErbB inhibitor showed effects on the 
growth activity and on ErbB-triggered signaling. In contrast, the difference 
between sensitivity and resistance of the ovarian cancer cell lines did not vary 
as much.  
The project delineated the effect of the drug on major signaling pathways 
downstream of the ErbB family of receptor tyrosine kinases (RTKs) in these two 
human breast cancer cell lines. The examined effects of pelitinib were drug-
dependent inhibition of EGFR, of ErbB2 and of ERK1/2 phosphorylation in both 
pelitinib-sensitive and pelitinib-resistant cells. Interestingly, phosphorylation of 
AKT at Ser473 and Thr308 was only blocked in sensitive SKBR3, but not in 
resistant T47D, suggesting that inhibition of ERK1/2 downstream signaling is 
not sufficient for drug-dependent growth arrest. Moreover, transfection of a 
constitutively active AKT, but not of constitutively active MEK1, in SKBR3 
induced resistance to pelitinib. This data suggests crucial roles of the PI3K/AKT 
signaling pathway but not of the Erk1/2 pathway in determining 
sensitivity/resistance of the cells against pelitinib.    
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8 Zusammenfassung  
Brustkrebs ist eine potenziell tödliche Erkrankung bei Frauen und seine 
Pathogenität steht im Zusammenhang mit den ErbB Tyrosinkinase Rezeptoren. 
Diese Familie besteht aus vier gleichartigen Mitgliedern: ErbB-1/HER-1/EGFR, 
ErbB-2/HER-2/Neu, ErbB-3/HER-3 und ErbB-4/HER-4. In Brustkrebs, und auch 
in Eierstockkrebs sind die EGFR und ErbB-2 Rezeptoren überexpremiert. Diese 
Rezeptoren stimulieren die Krebsentstehung, sorgen für klinisch aggressives 
Verhalten und schlechte Prognosen. Die Überexpression von EGFR und ErbB-
2 Rezeptoren macht sie deshalb zu perfekten Zielen für eine Therapie.  
Unsere Versuche konzentrierten sich auf die zwei Brustkrebslinien SKBR3 und 
T47D, welche jeweils sensibel gegenüber dem EGFR/ErbB-2 Inhibitor Pelitinib 
(EKB-569, Wyeth) oder resistent dagegen sind. Dieser neue irreversible 
Inhibitor hat einen Effekt auf das Wachstum der Zellen und auf die ErbB 
getriggerte Signaltransduktion. Im Gegensatz dazu ist der Unterschied 
zwischen Sensibilität und Resistenz bei den Eierstockkrebszellen nicht so groß.  
Dieses Projekt beschreibt die Effekte dieses Medikaments in den zwei 
Brustkerbs Zelllinien auf die Hauptsignalwege die unterhalb der ErbB 
Tyrosinkinase Rezeptoren (RTKs) liegen. Die untersuchten Effekte von Pelitinib 
beziehen sich auf die Inhibierung der Phosphorylierung von EGFR, ErbB-2 und 
ERK1/2 in den sensiblen und resistenten Zelllinien. Interessanterweise wird die 
Phosphorylierung von AKT nur in den sensiblen SKBR3 gehemmt aber nicht in 
den resistenten T47D, dies führt zu der Annahme, dass die Inhibierung vom 
ERK1/2 Signalweg nicht ausreicht für die Inhibierung des Zellwachstums. Die 
Transfection von SKBR3 mit dem konstitutiv aktiven AKT führt im Gegensatz 
zum konstitutiv aktiven MEK1 zu einer induzierten Resistenz gegenüber 
Pelitinib. Diese Daten zeigen uns die wichtige Rolle vom PI3K/AKT Signalweg, 
nicht vom ERK1/2 Signalweg, der entscheidend ist für die Sensibilität/Resistenz 
der Zelllinien gegenüber Pelitinib.    
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10  Abbrevations 
APS    ammonium persulfat  
CIAP   calf intestine alkaline phosphatase 
DMSO  dimethyl sulfoxide 
DOC   2,5-dimethoxy-4-chloroamphetamine 
ECL   enhanced chemiluminescence 
EDTA    ethylene-diamine tetraacetic acid  
EGTA   ethylene glycol tetraacetic acid 
EGF    epidermal growth factor  
EGFR   epidermal growth factor receptor   
ER   estrogen receptor 
ErbB-2   epidermal growth factor 2 
ErbB-3   epidermal growth factor 3 
ErbB-4   epidermal growth factor 4 
ERK    extracellular signal- regulated kinase  
FCS    fetal calf serum  
GFP   green fluorescence protein 
GSK-3   glycogen synthase-3  
HB-EGF   heparin-binding EGF  
HRP   horseradish peroxidase  
HRG   heregulin 
IGF   insulin-like growth factor 
IGF-1R   insulin-like growth factor-1 receptor  
Jak    janus tyrosine kinases  
MAPK   mitogen-activated protein kinase  
MEK1/2 MAP  kinase ERK kinase (=MAPKK 1/2)  
mTOR   mammalian target of rapamycin 
NaCl    sodium chloride  
NaF    sodium fluoride  
NRGs   neuregulins  
NSCLC   non small cell lung cancer  
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PAA   polyacrylamide 
PAGE   polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline  
PDK1   phosphoinositide dependent kinase  
PH   pleckstrin homology domain  
PI3K    phosphatitylinositol-3 kinase  
PKP   protein kinase B 
PPP    Picropodophyllin  
PR   progesterone receptor 
PTB    phosphotyrosine binding  
PTEN  phosphatase and tensin homologue deleted from 
chromosome 10  
PVDF    polyvinylidene fluoride  
RTK    receptor tyrosine kinase  
RTKI   receptor tyrosine kinase inhibitor 
SDS    sodiumdodecylsulfat  
SH    scr homology domain  
STAT   signal transducer and activator of transcription  
TBE t   ris borat EDTA buffer  
TEMED   N,N,N´,N´,- tetramethylethylendiamine  
TGF
  
transforming growth factor 
Tris    tris(hydroxymethyl)-aminomethan            
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